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ROLE OF PDE4 IN ALCOHOL-INDUCED PATHOGENIC ALTERATIONS IN 
THE GUT-LIVER-BRAIN AXIS 
 
Diana Veronica Avila 
April 12th 2016 
Alcoholic liver disease (ALD) remains a leading cause of death from liver 
disease in the U.S., and there is still no FDA-approved therapy. Alcohol 
metabolism leads to generation of free radicals and oxidative stress with a 
resultant formation of lipid peroxidation products, which, in turn, contribute to the 
development of ALD. Alcohol induced hepatic steatosis is the earliest and most 
frequent manifestation of ALD and a significant risk factor for progressive liver 
disease. Cyclic adenosine monophosphate (cAMP) signaling has been shown to 
significantly regulate lipid metabolism. Moreover, agents that increase cAMP 
have been shown to effectively mitigate oxidative stress both in vivo and in vitro. 
Hence, the role of hepatic PDE4 and a resultant dysregulation of cAMP signaling 
in alcohol induced hepatic steatosis and lipid peroxidation was examined. 
C57BL/6 wild type (WT) and Pde4b knockout (Pde4b-/-) mice were pair-fed 
control and ethanol liquid diets. One group of wild type mice received Rolipram, a 
PDE4 specific inhibitor, during alcohol feeding. Alcohol feeding resulted in a 
significant fat accumulation and oxidative stress in WT mice as demonstrated by 
increased hepatic free fatty acid levels and lipid peroxidation. This alcohol effect
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was associated with a significant decrease in hepatic carnitine 
palmitoyltransferase 1A (CPT1A) expression, a rate limiting enzyme in fatty acid 
β-oxidation.  Additionally, hepatic F4/80 staining was markedly increased in 
alcohol fed WT mice, indicating Kupffer cell activation. Importantly, alcohol 
feeding significantly increased hepatic PDE4 enzyme expression as early as in 
one week with the concomitant decrease in cAMP/pCREB levels. PDE4 inhibition 
in alcohol fed mice prevented the decrease in hepatic CPT1A expression and 
lipid accumulation. This effect on CPT1A expression was mediated by preventing 
the decrease in a critical transcription factor for CPT1A expression, peroxisome 
proliferator-activated receptor (PPARα) and increase in PPARα co-activators, 
peroxisome proliferator-activated receptor gamma coactivator 1α  and sirtuin 
1(PGC-1α and SIRT1). Moreover, compared to wild type mice, Pde4b knockout 
and Rolipram treated alcohol fed mice had higher levels of antioxidant enzymes 
SOD1/2, and GPx1/2 and decreased 4HNE and F4/80 staining. In summary, 
these results demonstrate that the alcohol- induced increase in hepatic PDE4, 
specifically PDE4B expression, and compromised cAMP signaling predisposes 
the liver to impaired fatty acid oxidation and increased oxidative stress. These 
data also suggest that hepatic PDE4 is a clinically relevant therapeutic target for 





Chronic ethanol consumption significantly increases brain TLR4 
expression and downstream inflammatory gene expression, contributing to 
microglial activation and neuro-inflammation. Our group has previously shown 
that TLR4 inducible PDE4 expression plays a major role in regulating 
inflammatory cytokine production in alcohol exposed monocytes/macrophages. 
We have also shown that inhibition of PDE4 markedly down-regulates endotoxin 
inducible TNF expression and alcohol mediated priming of 
monocytes/macrophages. In the present study we examined the potential role of 
PDE4 in alcohol induced activation of glial cells and neuro-inflammation using 
both in vitro and in vivo models. Primary mouse microglial cells were treated in 
vitro with ethanol followed by endotoxin stimulation. Protein and gene expression 
analysis showed that alcohol treatment increased TNF and PDE4B expression 
and primed microglial cells to increase production of TNF in response to 
endotoxin. The PDE4 inhibitor, Rolipram, significantly attenuated TNF expression 
indicating the role of PDE4B in alcohol mediated effect on microglial TNF 
expression. To examine the role of PDE4B in alcohol induced neuro-
inflammation in vivo, C57Bl/6 and pde4b knockout (Pde4b-/-) mice were pair-fed 
control and ethanol liquid diets for 4 weeks. Additionally, one group of mice 
received Rolipram to pharmacologically inhibit PDE4 activity. Examination of 
brain tissues from alcohol fed mice showed increased PDE4B protein expression 
compared to pair-fed mice. Along with PDE4B, alcohol was also observed to:  (i) 
increase COX-2 expression; and (ii) induce activation of glial cells, as indicated 
by an increase in GFAP (glial fibrillary acidic protein) positive astrocytes, and 
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IBA-1 (ionized calcium-binding adapter molecule 1) positive microglial cells. 
Importantly, both alcohol-induced activation of glial cells and inflammation were 
markedly attenuated in Pde4b-/- mice and by pharmacologic inhibition of PDE4. 
Overall, these data identify the critical role of PDE4B in regulating alcohol-
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I. Background and rationale 
Excessive alcohol consumption is the third leading cause of preventable 
death in the United States, [1, 2]. Centers for Disease Control and Prevention 
(CDC) estimates about 88,000 deaths per year related to excessive alcohol 
consumption in the U.S. [3, 4]. Alcohol has been part of the human lives since 
the Stone Age. The earliest evidence of alcohol consumption was found in China, 
5000 B.C. [5].  Alcohol consumption has increased since then; the 
industrialization and marketing promoted alcohol consumption worldwide [6] 
resulting in an increase in alcohol-induced chronic diseases, including alcoholic 
liver disease, alcohol-induced acute pancreatitis, and degeneration of nervous 
system among others [6]. Alcohol-induced diseases have been traditionally 
viewed as organ-specific diseases. In this regard, important scientific advances 
have been made in our understanding of alcohol’s effects on individual systems 
such as brain, liver, gastrointestinal, immune, cardiovascular, and endocrine 
systems. However, interactions between different organ systems in the presence 
of alcohol are only beginning to be investigated. There are emerging data 
suggesting that these interactions could provide important insights into the 
mechanisms by which alcohol-induced pathology in one organ influences the 
functioning of other organs, leading to the multiple organ dysfunction associated
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with alcohol abuse. However, gaps remain in understanding of underlying 
molecular mechanism(s) that contribute to altered expression of genes involved 
in alcohol-induced organ injury. 
Alcohol consumption leads to the development of inflammation and injury 
in different organs including liver and brain. Previous studies in our group have 
shown that alcohol induced PDE4 expression and a resultant decrease in cAMP 
signaling plays a critical role in increased response of monocytes/macrophages 
to endotoxin [7, 8]. Moreover, PDE4 enzymes have been shown to play a 
pathogenic role in hepatic inflammation and injury [9]. Based on these 
observations, we hypothesized that upregulation of PDE4 expression and 
resulting decrease in cAMP signaling play a critical role in alcohol induced 
pathogenic alterations in the gut-liver-brain axis and the development of 












Alcohol-induced PDE4 expression and decreased cellular cAMP levels 









Figure 1. General Hypothesis. Alcohol increases gut permeability and 
causes changes in gut microbiome (dysbiosis); Translocation of microbial 
products, e.g. endotoxin to systemic/portal circulation affects many organs 
including the liver and the brain. Resident macrophages in the liver (Kupffer cells) 
get activated by endotoxin and produce pro-inflammatory cytokines/chemokines 
and reactive oxygen species resulting in the development of inflammation and 
dysregulation of lipid synthesis in the liver. Moreover, alcohol affects glial cells 
and induces their activation which in turn leads to the production of 
proinflammatory cytokines in the brain. Additionally, Kupffer cell-derived pro-
inflammatory cytokines and mediators are released into systemic circulation, 
translocate through blood brain barrier and contribute to increased activation of 





II. Alcohol metabolism and oxidative stress 
Alcohol is mostly metabolized in the liver by three enzymes: alcohol 
dehydrogenase (ADH), cytochrome P4502E1 (CYP2E1) and catalase.  
ADH is located in the cytosol/mitochondria and metabolizes alcohol into a highly 
toxic byproduct aldehyde, acetaldehyde simultaneously increasing the production 
of free radicals and NADH/NAD ratio [10-12]. Oxidative metabolism of alcohol by 
microsomal CYP2E1 also leads to the production of acetaldehyde and reactive 
oxygen species e.g. superoxide anion, hydroxyl radicals [10-12]. Alcohol 
metabolism by catalase (found in the peroxisomes) also produces acetyldehyde, 
however this pathway has a minor role in alcohol metabolism compared to other 
two enzymes, ADH and CYP2E1 [12]. Acute alcohol consumption is only partly 
metabolized by CYP2E1, whereas, chronic alcohol consumption is mostly 















Figure 2. Oxidative metabolism of alcohol.  Enzymes involved in alcohol 
metabolism: alcohol dehydrogenase (ADH), cytochrome P450 2E1 (CYP2E1), 
and catalase. ADH converts ethanol into acetaldehyde in cytosol. CYP2E1 
converts ethanol into acetaldehyde in microsomes, and catalase metabolizes 
ethanol into acetaldehyde in peroxisomes. As a result, alcohol metabolism 
generates acetaldehyde adducts, reactive oxygen species and increases the 




Alcohol metabolism and activation of Kupffer cells increases the 
generation of reactive oxygen species (ROS) [12, 15]. The increased production 
of free radicals and non-radical species can attack lipids composed of carbon-
carbon double bonds such as polyunsaturated fatty acids (PUFAs), which can 
lead to reactive aldehyde products such as malondialdehyde (MDA), 4-hydroxy-
2-nonenal (HNE), 4-hydroxy-2-hexenal (4-HHE) [16-18]. These aldehydes 
interact with proteins and form protein adducts such as malondialdehyde-
acetaldehyde (MAA) [12]. It has been shown that MAA-adducts, can increase 
production of pro-inflammatory cytokines/chemokines and contribute to the 
development of ALD [15, 19]. 
Oxidative stress is mainly characterized by increased ROS/RNS 
generation and decreased antioxidant capacity [20]. In order to maintain 
homeostasis, organisms use non-enzymatic/ enzymatic scavengers and 
quenchers known as antioxidants. These antioxidants can donate electrons to 
the free radicals converting them into less toxic molecules. Antioxidants are able 
to lower oxidative stress, DNA mutations and prevent cell damage [20-23]. In 
order for the cell to maintain homeostasis, it contains the following endogenous 
antioxidant enzymes superoxide dismutase (SOD), catalase, glutathione 
peroxidase (GPx), and non-enzymatic antioxidants, like glutathione (GSH), 
ferritin, transferrin, ceruloplasmin, albumin, and low-molecular scavengers [20]. 
Importantly, alcohol exposure has been associated with decreased glutathione 
(GSH) content, decreased nuclear factor (erythroid-derived 2)-like 2 (Nrf2) 
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expression and activity of antioxidant enzymes (e.g. SOD, GPX) in humans as 
well as in animal studies [24-30].  
Superoxide dismutases (SOD) are a group of oxidoreductases, which 
convert superoxide radical into hydrogen peroxide and molecular oxygen. There 
are three isoforms of SODs, Cu-Zn SOD (SOD1), MnSOD (SOD2), ecSOD 
(SOD3) [31-33]. SOD1 (32 kDa) is mostly found in the cytoplasm, but it can also 
be found in the nucleus and lysosomes. SOD2 (23 kDa) is located in the 
mitochondria. SOD3 (135 kDa) is extracellular enzyme found  in the human 
plasma, lymph, ascites, and cerebrospinal fluids [34]. The common enzymatic 
activity of SODs is the alternate reduction and re-oxidation of a catalytic metal 
copper or manganese at the active site of the enzyme [33]. There are eight types 
of glutathione peroxidases (GPX1-GPX8) that covert hydrogen peroxide into 
water. Liver predominantly expresses GPX1 and GPX2. Catalases also can 
serve detoxifying enzymes by converting hydrogen peroxide into oxygen and 
water [32, 35]. In this regard, it has been shown that overexpression of SOD1 
and SOD2 protect from alcohol induced liver injury [36-38]. 
NF-E2-related factor 2 (Nrf2) is a critical transcription factor for several 
antioxidant enzymes [39, 40]. Nrf2 binding to antioxidant response element 
(ARE) will promote the transcription of antioxidant enzymes such as superoxide 
dismustases (SODs), catalase, peroxidases, and GST-transferases [39, 40]. Nrf2 
activity is controlled by Keap1 (Kelch-like ECH-associated protein 1)-dependent 
as well as independent pathway. Under normal conditions, Nrf2 is complexed 
with Keap1-cullin 3 (Cul3). Keap1-Cul3 has ubiquitin ligase activity which controls 
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Nrf2 levels through ubiquitin-proteasome degradation pathway [40]. Under 
oxidative stress conditions, redox status of Keap1 cysteine residues undergoes 
changes leading to Keap1 protein modification. This modification results in 
changes in Keap1/Cul3 complex ligase activity and stabilization of Nrf2 protein 
allowing Nrf2 to move into the nucleus [40, 41]. With regard to Keap1-
independent control, de novo synthesis of Nrf2 has been recently described as a 
mechanism of Nrf2 activation under oxidative stress conditions [40]. Importantly, 
alcohol fed Nrf2-/- knockout mice have increased oxidative stress, inflammation, 
lipid accumulation and liver injury [42, 43].  
In summary, alcohol metabolism and ensuing oxidative stress plays a critical 
role in the development of alcoholic liver disease.  
 
III. Alcoholic fatty liver disease 
Ninety percent of people consuming alcohol develop hepatic steatosis [44, 45]. 
Steatosis is a condition characterized by the increase of lipid droplets, 
triglycerides and cholesterol in the liver [46, 47]. Hepatic steatosis is the initial 
stage of alcoholic liver disease and the first response to chronic and acute 
alcohol consumption. Although alcohol-induced hepatic steatosis is reversible 
and considered to be benign, it is well-established that it predisposes the liver to 
more advanced pathologies such as alcoholic steatohepatitis (ASH), hepatic 
fibrosis, cirrhosis and even hepatocellular carcinoma [48-50]. Alcohol induced 
hepatic steatosis is mediated by increased de novo lipogenesis and impaired 
fatty acid beta-oxidation [51]. Several studies have identified the genes involved 
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in alcohol induced dysregulation of lipid metabolism leading to steatosis [52, 53]; 
however, gaps remain in understanding of underlying molecular mechanism(s) 
that contribute to altered expression of genes involved in hepatic lipogenesis.  
 
IV. Alcohol mediated de novo lipogenesis in the liver  
Lipid accumulation due to chronic alcohol consumption was first 
recognized by Lieber in 1975 [54, 55]. Hepatic lipid synthesis is accelerated after 
ethanol consumption and is associated with higher expression of lipogenic 
genes/enzymes, including fatty acid synthase (FASN), acetyl-CoA carboxylase 
(ACC), ATP citrate lyase (ACL), stearoyl CoA desaturase (SCD), and malic 
enzyme (ME) [52, 53]. Sterol regulatory element binding protein-1c (SREBP-1c) 
is a transcription factor that plays an important role in regulating the expression 
of all alcohol induced lipogenic genes (e.g. ACC, FAS). Several studies have 
shown that alcohol increases SREBP-1c expression and activation [47, 56-58].  
5’ AMP-activated protein kinase (AMPK) plays a key role in lipid  
metabolism by regulating both lipid synthesis and fatty acid β-oxidation [59]. 
AMPK is a serine/threonine heterotrimeric kinase composed of one catalytic 
alpha-subunit and two regulatory beta and gamma subunits [59]. AMPK is 
activated by the increase in the AMP/ADP ratio and phosphorylation of the AMPK 
threonine 172 residue by upstream kinases such as LKB1-STRAD-MO25 [59]. 
Activated AMPK inhibits the synthesis of fatty acids by phosphorylating acetyl-
CoA carboxylase (ACC), which prevents the production of more malonyl-CoA, (a 
rate-limiting step in lipid synthesis) [50, 60, 61]. In the context of alcohol, chronic 
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alcohol consumption has been shown to inhibit AMPK by inhibiting the 
phosphorylation of  AMPK through  inactivation of upstream kinases such as 
AMPK kinase (AMPKK) or liver kinase B1 (LKB1) [62].  
 
V. Alcohol effect on mitochondrial fatty acid oxidation  
Along with the up-regulation of fatty acid biosynthesis by ethanol, down-
regulation of fatty acid oxidation is also a critical component in the development 
of alcohol-induced hepatic steatosis. There are different types of free fatty acid 
oxidation: alpha, beta, and omega oxidation [63]. Beta-oxidation can occur in 
mitochondria as well as peroxisomes [63]. Regarding the changes in β-oxidation 
mediated by alcohol, it has been demonstrated that alcohol significantly impairs 
mitochondrial free fatty acid β-oxidation [63]. In mitochondrial β-oxidation, FFAs 
are activated in the cytosol by acyl-CoA synthase and oxidized in the 
mitochondria. These FFAs are converted into acyl-carnitine by carnitine 
palmitoyltransferase-1 (CPT-1A) and transported to the mitochondrial matrix. 
FFAs are further oxidized into acetyl-coenzyme A (acetyl-CoA), which is reduced 
in the tricarboxylic acid (TCA) cycle, resulting in formation of NADH and FADH 
[64]. CPT-1A is a key enzyme in free fatty acid β-oxidation, which has been 
shown to be decreased by chronic alcohol feeding in rodents [65, 66]. Our group 
has shown that decrease in Cpt1a gene expression by binge alcohol 
consumption is mediated by increased HDAC3 levels [67]. Specifically, it has 
been shown that when HDAC3 binds to Cpt1a promoter in the thyroid response 
element (TRE) binding region, this results in increased binding of nuclear 
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suppressor N-CoR leading to a suppression of Cpt1a gene[67]. In addition to 
transcriptional suppression of Cpt1a, alcohol has been shown to result in 
decreased activity of this enzyme [68]. Specifically, malonyl-CoA, which is 
formed from acetyl-CoA in the carboxylase reaction by ACC enzyme, 
allosterically binds CPT-1A and inhibits its activity [69].  
 
VI. Regulation of CPT-1A expression and modulation by alcohol  
CPT1 expression is regulated by a complex transcriptional machinery 
involving several transcription factors (TF) and co-activators including, PPAR-α, 
PGC-1α, SIRT1, CREB, HNF4-α etc. [70-72]. In alcohol induced hepatic 
steatosis, ethanol exposure has been shown to decrease PPARα and PGC-1α 
expression/activity, as well as HNF4-α transcriptional activity resulting in the 
reduction of CPT1A mRNA levels and β-oxidation [26, 73-77].  
Another critical transcription factor that plays an important role in the 
expression of CPT-1 is peroxisome proliferator-activated receptor α (PPARα) 
[76]. PPARα was first identified in the early 1990s, as a genetic sensor for fats 
[78, 79]. PPARα belongs to the nuclear hormone receptor superfamily and   
highly expressed in the liver [80, 81]. Long-chain fatty acids are the endogenous 
ligands of PPAR-α [81]. Once PPAR-α is activated by the ligand, PPAR-α moves 
into the nucleus forming a complex with co-receptor retinoic X receptor (RXR) 
and its co-activator PPAR gamma coactivator-1α (PGC-1α). This complex binds 
to the PPAR response element (PPRE) in the nucleus [81, 82]. Ethanol 
administration decreases the transcriptional activity of PPARα resulting in the 
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reduction of fatty acid oxidation via decreased CPT1A expression [26, 83-86]. 
Additionally, acetaldehyde, a metabolite of alcohol, has been shown to inhibit 
PPAR binding to the promoter region by forming adducts with PPAR [87]. 
Notably, induction of PPARα, which, in turn, accelerates fatty acid oxidation, 
prevents ethanol induced fatty liver [84].  
It is well established that optimal transcriptional activity of PPAR-α 
requires a formation of a complex with its critical co-activator PGC-1α [70, 72]. 
PGC-1α interacts and recruits proteins with histone acetylating activities which 
results in transcriptionally permissive promoter histone modification allowing 
increased transcription factor binding [88].  PGC-1α, in turn, has to be de-
acetylated by SIRT1 to function as a co-activator [89, 90]. The roles of PGC-1α 
and SIRT1 in promoting PPAR-α mediated fatty acid β-oxidation have been 
extensively studied in alcohol induced hepatic steatosis. Specifically, it has been 
shown that alcohol decreases PGC-1α activity via impaired SIRT1 function 




VII. Effect of cAMP on hepatic lipogenesis and fatty acid oxidation 
The role of cAMP in regulation of both hepatic lipogenesis as well as fatty 
acid oxidation is well established. It has been shown that cAMP decreases 
SREBP-1c mRNA levels in hepatocytes and the whole liver along with lipogenic 
target genes [94, 95]. Further, cAMP/PKA phosphorylates LXRα and prevents 
dimerization with the retinoid X receptor, which causes impaired DNA binding 
activity of SREBP-1c [95]. In relation to fatty acid oxidation, cAMP increases the 
transcriptional activity of all three PPAR isotypes via cAMP-dependent PKA 
phosphorylation. Specifically, PKA activators have been shown to increase 
PPAR-α activity and DNA binding stability [96]. Early studies on hepatocytes 
showed how cAMP analogs can increase CPT-1 expression [97, 98]. Specifically, 
it has been shown that cAMP promotes CPT1A transcription via upregulation of 
PGC-1α gene expression and increased binding of HNF4α and CREB to CPT1A 




VIII. Regulation of cAMP levels by phosphodiesterases and alcohol 
Intracellular levels of cAMP are tightly regulated by the coordinated control 
of its synthesis via adenylyl cyclase, and its degradation via a large family of 
phosphodiesterases (PDEs). An increase in cAMP levels triggers a signaling 
cascade leading to regulation of numerous protein activities and gene expression. 
Duration and amplitude of cAMP signaling is controlled exclusively by PDEs via 
cAMP degradation. Hence, any changes in PDE expression will have a 
significant effect on cAMP signaling. Among three cAMP specific PDEs (PDE3, 
PDE4 and PDE7), the PDE4 family is the largest and most ubiquitous, with 4 
genes (PDE4A/B/C/D) encoding over 20 distinct PDE4 isoforms [101, 102]. 
PDE4 is the current therapeutic target of selective inhibitors for the treatment of 
inflammatory diseases, such as asthma and chronic obstructive pulmonary 
disease, as well as depression and cognitive deficits [101, 102].  
With regard to alcohol effect on cAMP levels, previous studies have 
shown that alcohol affects G protein-coupled receptor stimulated cAMP 
production in various immune cells through changes in the expression of G 
protein -αs (G-αs) which stimulates adenylyl cyclase to produce cAMP [103]. An 
effect of alcohol on receptor stimulated cAMP production has also been shown in 
isolated hepatocytes; however the effect was dependent on alcohol 
concentration [104, 105]. Specifically, acute exposure of hepatocytes (48 h) with 
alcohol concentration up to 50 mM had a suppressive effect, whereas high 
concentrations (50-100 mM) resulted in increased production of cAMP in 
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response to glucagon and adenosine [104, 105]. However, alcohol had no effect 
on the basal adenylyl cyclase activity [105].  
Our group has previously shown that chronic alcohol exposure 
significantly upregulates PDE4(B) expression and decreases cellular cAMP 
levels in monocytes/macrophages and Kupffer cells [7, 8]. Importantly, alcohol 
mediated upregulation of PDE4 expression/activity has been demonstrated to 
play a causal role in phenotypic changes of macrophages to produce elevated 
levels of inflammatory cytokines [7, 8]. Additionally, our group has shown that 
PDE4 enzymes play pathogenic role in the development of hepatic inflammation 






Alcohol-induced PDE4 expression and decreased cellular cAMP levels play 




































MATERIALS AND METHODS 
Animal Model: Male C57Bl/6 mice (3 months of age) were obtained from the 
Jackson Laboratory (Bar Harbor, ME). A breeding pair of Pde4b knockout mice 
generated on C57Bl/6 background was a kind gift from Prof. Marco Conti (UCSF). 
Mice were housed in a pathogen-free, temperature-controlled animal facility with 
12- hour light ⁄ 12 hour dark cycles. All experiments were carried out according to 
the criteria outlined in the Guide for Care and Use of Laboratory Animals and 
with approval of the University of Louisville Animal Care and Use Committee. 
C57BL/6 and Pde4b knockout male mice were pair-fed Lieber-DeCarli liquid diet 
(Lieber-DeCarli type, Bioserv, Frenchtown, NJ) containing either alcohol (AF) or 
isocaloric maltose dextrin (PF) for 4 weeks. Alcohol was gradually increased over 
a period of one week and then mice were fed the ethanol diet [6% (v⁄v)] ad 
libitum for 4 weeks (AF). The control pair-fed (PF) mice were given the isocaloric 
liquid diet. Additional groups of AF and PF animals were treated with PDE4 
specific inhibitor, rolipram at 5 mg/kg, 3 times a week for 4 weeks. Rolipram 
(C16H21NO3) (Biomol, Enzo Life Sciences, Farmingdale, NY) was dissolved in 
sterile DMSO and diluted with sterile phosphate buffered saline just before 
injection. Wild type mice without rolipram treatment were sacrificed at 1, 2 and 4 
weeks after starting 6% alcohol. Pdeb4-/- mice and wild type mice treated with 
rolipram were sacrificed after 4 weeks of feeding. At sacrifice, mice 
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were anesthetized with intraperitoneal injection of Nembutal, 80mg/kg. Whole 
blood was collected from the inferior vena cava in a heparinized syringe and 
centrifuged at 7000g for 7 minutes at 4°C. Plasma aliquots were stored at -80°C 
for analysis. Liver tissue was cut into small pieces, snap-frozen in liquid nitrogen 
and stored at -80°C. An additional liver piece was fixed in 10% neutral-buffered 




















Figure 4. Experimental Design. A) Schematic time line of alcohol feeding and 
Rolipram treatment. Wild type (WT, C57BL/6J) and PDE4B-/- mice were fed 
control (pair-fed) and alcohol (alcohol-fed) diet with and without Rolipram 
treatment. B) Caloric profile of diet: control and alcohol diets have the same 
amount of kcal/L; however 36% of carbohydrate calories in control diet is 







Western blot analysis: Liver (50 mg) tissue was lysed using RIPA buffer 
containing protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) and 
serine/threonine phosphatase inhibitor sodium fluoride and phosphotyrosine 
phosphatase inhibitor sodium orthovanadate. Proteins (25 µg) were analyzed by 
SDS-polyacrylamide gel electrophoresis using a Bio-Rad (Hercules, CA) 
electrophoresis system. Immunoreactive bands were visualized using the 
enhanced chemiluminescence light detection reagents (Amersham, Arlington 
Heights, IL). Detection of GAPDH served as a loading control. Quantification was 
performed with Image LabTMSoftware (BioRad, Life Science Research, 
Hercules, CA). PDE4A, B, D,C, CPT-1A, PGC-1α, PPAR-α, SIRT-1, Histone 3, 
SOD1, SOD2, Gpx-1, Gpx-2, catalase, NRF-2 and β-actin antibodies were 
purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX).pACC andpAMPK 
antibodies was purchased from Cell Signaling (Boston, MA). 
RNA isolation and real-time PCR analysis: Total RNA was isolated from 50mg 
liver and brain tissue using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). For 
RT-qPCR, the first-strand cDNA was synthesized using qScript cDNA SuperMix 
(Quanta Biosciences, Inc., Gaithersburg, MD). qRT-PCR was performed in  
triplicate with an ABI Prism 7500 sequence detection system and PerfeCTa 
SYBR Green FastMix, Low ROX reagents (Quanta Biosciences). The specific 
primers were purchased from integrated DNA technologies (IDT) (Coralville, 
Iowa). The parameter Ct (threshold cycle) was defined as the fraction cycle 
number at which the fluorescence passed the threshold. The relative gene 
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expression was analyzed using 2-ΔΔCt method by normalizing to 18S gene 
























Mouse Pde4a   
Pde4a_F  5'-CACAGCCTCTGTGGAGAAGTC-3' 
Pde4a_R  5'-GTGATACCAATCCCGGTTGTC-3' 
Mouse Pde4b   
Pde4b_F  5'-GACCGGATACAGGTTCTTCG-3' 
Pde4b_R  5'-CAGTGGATGGACAATGTAGTCA-3' 
Mouse/Rat Pde4c   
Pde4c_F 5'-TTTCTCATCAACACCAACTCAGA-3' 
Pde4c_R 5'-CTGCAGGAGCTTGAAGCCTA-3' 
Mouse Pde4d   
Pde4d_F  5'-TGTCCACAGTCAACGCCGGGAG-3' 
Pde4d_R  5'-CCAAGACCTGAGCAAACGGGGTCA-3' 
Mouse Cpt1a   
Cpt1a_F 5'-GCTGCACTCCTGGAAGAAGA-3' 
Cpt1a_R 5'-GGAGGGGTCCACTTTGGTAT-3' 




(Ppargc1a)   
Ppargc1a_F 5'-ACAGCTTTCTGGGTGGATTG-3' 
Ppargc1a_R 5'-CGCTAGCAAGTTTGCCTCAT-3' 
Mouse Sirt1  
Sirt1_F 5’-CAGACCCTCAAGCCATGTTT-3’ 
Sirt1_R 5’-ACACAGAGACGGCTGGAACT-3’ 
Rat Pde4a  
Pde4a_F 5’-ATGGCTGAGTTCTTCCAGCA-3’ 
Pde4a_R 5’-CCATGTCTCCCACAATGGAT-3’ 




















Table 1. Primers for quantitative reverse transcriptase-PCR 
  
Pde4b_R 5’- CAATGAAACCAACCTGGGACT-3’ 
Rat Pde4d  
Pde4d_F 5’-TGGATCATCCTGGTGTGTCA-3’ 
Pde4d_R 5’-TTAAAGCCCACAGCCAAATG-3’ 
Rat Cpt1a  
Cpt1a_F 5’-CTGCATGGAAGATGCTTTGA-3’ 
Cpt1a_R 5’-GCCATGACATACTCCCACAA-3’ 
Rat Sirt1  
Sirt1_F 5’- CCTTTCAGAACCACCAAAGC-3’ 
Sirt1_R 5’- TGAAGTCAGGTATCCCACAGG-3’ 
Rat Sod1  
SOD1_F 5’- AAGCGGTGAACCAGTTGTG -3’ 
SOD1_R 5’- TCCAACATGCCTCTCTTCATC -3’ 
Rat Sod2  
SOD2_F 5’- GGCCAAGGGAGATGTTACAA -3’ 
SOD2_R 5’- GCTTGATAGCCTCCAGCAAC -3’ 
Rat Nfe2  
NFE2_F 5’- GGAGCTTGGAGAGATGGAACT -3’ 




Immunohistochemistry: Commercially available antibody against CPT-1A 
pCREB, 4-HNE, Acrolein, F4/80, GFAP were used for immunohistochemical 
analysis. Assays were performed according to the manufacturers’ protocols. 
Oil Red O staining: Frozen liver sections were washed in phosphate buffered 
saline twice for 5 minutes. Oil-Red-O and 85% propylene glycol were added with 
agitation for 15 minutes, followed by washing in tap water. 
Blood alcohol levels: Blood alcohol levels were measured in freshly drawn 
samples using Ethanol Assay Kit (Sigma, St. Louis, MO), according to the 
manufacturer's instructions. Whole blood was centrifuged at 40C and plasma was 
diluted prior to measurement. 
Primary hepatocyte culture: Primary hepatocytes were isolated from livers of 
Sprague Dawley male rats as described previously [106]. Treatments were 
performed 24 hours after isolation.   
Hepatic Free Fatty Acids: hepatic tissue (100 mg) was homogenized in 1 ml of 
50 mM NaCl. The homogenate (500 μl) was mixed with chloroform/methanol 
(2:1, 4 ml) and incubated overnight at room temperature with gentle shaking. 
Homogenates were vortexed and centrifuged for 5 min at 3000g. The lower lipid 
phase was collected and concentrated by vacuum. The lipid pellets were 
dissolved in 1% Triton X100 in phosphate-buffered saline and nonesterified-fatty 
acid (NEFA) were assayed using a commercially available kit HR Series NEFA-
HR(2) from Wako Chemical USA (Richmond,VA). 
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Measurements of cAMP levels: Hepatocytes, liver tissues were homogenized 
in 0.1N HCl and assayed according to the manufacturer instruction. cAMP ELISA 
kit was purchased  from Enzo Life Sciences (Farmingdale, NY). 
pCREB IHC analysis: The pCREB positive (3,3'-diaminobenzidine-stained in 
brown) and negative (hematoxylin-stained in blue) cells were counted using a 
freely available image analysis software http://www.cellprofiler.org [107]. 
Statistical Analysis: Statistical analysis was performed using GraphPad Prism 
Software. Data are presented as the mean ± standard deviation (SD). Statistical 
significance was calculated using one-way ANOVA followed by Bonferroni’s Test 








Alcohol upregulates hepatic pde4 expression leading to decreased levels 
of cAMP 
To address the potential pathogenic role of PDE4 in the development of 
alcohol induced hepatic steatosis, hepatic PDE4 expression was initially 
analyzed in mice fed control (pair-fed, PF) and alcohol (alcohol-fed, AF) diet. A 
significant up-regulation of mRNA expression for all PDE4 sub-families, PDE4A, 
B, C and D, was observed as early as following 1 week of alcohol feeding 
compared to controls (Figure 5A). Upregulated PDE4 expression continued for 
two weeks with a subsequent decline to baseline levels at 4 weeks (data not 
shown). Corresponding to the increased PDE4 expression, a sustained decrease 
in hepatic cAMP levels was observed in AF mice compared to PF mice (Figure 
5B).  Analysis of hepatocytes isolated from mice fed control and alcohol diet for 2 
weeks confirmed that alcohol feeding resulted in decreased hepatocyte cAMP 
levels (Figure 5C). Additionally, the effect of alcohol on PDE4 expression was 
examined on primary rat hepatocytes in vitro. Treatment of hepatocytes with 50 
mM alcohol for 48 hours led to a significant upregulation of PDE4A, B and C at 
both mRNA and protein levels (Figure 5D and E). These results show that 

















 Figure 5A and B. Alcohol increased PDE4 expression resulting in decreased 
cAMP levels in the liver.(A) mRNA levels of Pde4a, Pde4b, Pde4c, and Pde4d 
(n=5-7 in each group). (B) Hepatic cAMP levels after 1 and 2 weeks of alcohol 
feeding (n=5-7 in each group). Data are presented as mean ± S.D. *P < 0.05, 







Figure 5C. Alcohol feeding lowers cAMP levels in hepatocytes. Hepatocytes 
were isolated from WT mice fed control and alcohol diet for 2 weeks and cAMP 




















Figure 5D and E. Alcohol significantly increases PDE4 expression in primary 
hepatocytes in vitro. (D) mRNA levels of Pde4a, Pde4b, Pde4c, and Pde4d in 
primary rat hepatocytes after 48 hour of alcohol exposure (50 mM) (n=3). Data 
are presented as mean ± S.D. *P < 0.05, **P<0.01compared to UT. (E) 
Representative Western blot analysis of Pde4a, Pde4b, Pde4c, and Pde4d 






Pde4 inhibition prevents alcohol mediated fat accumulation in the liver 
To examine if increased expression of PDE4 enzymes and a resultant decrease 
in hepatic cAMP levels play a causal role in the development of alcohol induced 
hepatic steatosis, we employed both pharmacological (Rolipram) and gene-
knockout approaches (Pde4-/-) to block the activity of PDE4 and prevent the 
degradation of cAMP. Alcohol intake was carefully monitored throughout the 
feeding. No differences were observed in food consumption between the study 
groups. Importantly, alcohol inducible hepatic CYP2E1 as well as blood alcohol 
levels, were not significantly affected in Rolipram-treated or  Pde4b-/- mice, 
indicating that PDE4 inhibition does not influence ethanol metabolism (Figure 6A-
C). Notably, alcohol induced CYP2E1 protein levels showed higher induction 
compared to mRNA levels (Figure 6B) indicating that alcohol stabilized CYP2E1 
protein. This result is in agreement with previous studies demonstrating that 
alcohol prevents CYP2E1 proteolytic degradation by binding to CYP2E1 and 
inducing conformational changes [108, 109]. 
Histological analysis showed that alcohol feeding led to a significant hepatic fat 
accumulation in wild type mice, which was significantly attenuated in both  
Pde4b-/- and Rolipram-treated and mice (Figure 7A, B). Further, correspondent to 
the histological analysis, biochemical evaluation of hepatic free fatty acids also 







Figure 6. CYP2E1 expression and blood alcohol levels are not significantly 
affected by PDE4(B) inhibition. (A) Hepatic Cyp2e1 mRNA expression. (n=5-7 in 
each group). (B) Western blot analysis of hepatic CYP2E1 protein expression. 
(Representative western blot n=-5-7 in each group). (C) Blood alcohol levels after 
1 week alcohol feeding. Data are presented as mean ± SD (n=5-7 mice per 
group). *P<0.05, **P<0.01 
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Figure 7A and B. PDE4 inhibition attenuates alcohol induced lipid accumulation 
in the liver. (A) H&E staining. (B) Oil red O staining. Representative 
photomicrographs demonstrating lipid levels in the liver tissue.  
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Figure 7C. PDE4 inhibition attenuates alcohol induced lipid accumulation in the 
liver. (C) Hepatic free fatty acids (FFA). Data are presented as the mean ± SD, 











Pde4 inhibition prevents alcohol induced decrease in hepatic cAMP levels 
and CPT-1a expression 
Development of alcohol induced hepatic steatosis is significantly mediated 
by decreased expression of CPT1A, a rate limiting enzyme in fatty acid β-
oxidation [26, 67, 93]. Immunohistochemical staining of CPT1A in liver sections 
showed a decrease of CPT1A after 4 weeks of alcohol feeding in WT mice 
compared to WT pair fed mice (Figure 8A). In comparison, alcohol fed WT mice 
treated with Rolipram and Pde4b-/- mice showed no decrease of CPT1A 
compared to AF WT mice (Figure 8A). Quantitative real time PCR analysis of 
hepatic CPT1A mRNA levels also demonstrated that PDE4 inhibition prevented 
an alcohol mediated decrease in CPT1A mRNA (Figure 8B).  
Previous work has shown that in hepatocytes, cAMP induces CPT1A 
expression and involves cAMP response element binding protein (CREB) [71, 
110]. To examine whether the observed decrease in CPT1A expression by 
alcohol was a result of cAMP-mediated changes in phosphorylated CREB 
(pCREB) levels, we examined hepatic levels of pCREB. Correspondent to 
decreased hepatic cAMP levels in WT-AF mice, we observed decreased nuclear 
staining of active pCREB in WT-AF mice livers compared to WT-PF mice (Figure 
8C, D, E). By comparison, PDE4B inhibition in alcohol fed mice led to maintained 
levels of both cAMP and pCREB (Figure 8C, D), indicating that among PDE4 
sub-family of enzymes, PDE4B is primarily involved in the alcohol-inducible 






Figure 8A. PDE4 inhibition prevents alcohol induced decrease in hepatic CPT-1A 
expression.  Immunohistochemical staining with anti-CPT-1A antibody (×20 final 










Figure 8B. PDE4 inhibition prevents alcohol induced decrease in Cpt1a mRNA 
expression.  After 4 weeks of feeding hepatic Cpt1a mRNA levels were quantified 























Figure 8C. Alcohol mediated decrease in hepatic cAMP levels is prevented by 
PDE4(B) inhibition. After 2 weeks of alcohol feeding hepatic cAMP levels were 
measured using cAMP ELISA kit. Data are presented as the mean ± SD (n=5-7 





Figure 8D and E. PDE4 inhibition prevents alcohol-mediated decrease in hepatic 
pCREB levels. (D) Nuclear pCREB staining of livers after 4 weeks of alcohol 
feeding. (E) Quantification of immunohistochemical staining for hepatic pCREB 
levels as described in Methods. Data are presented as the mean ± SD 
(Representative photomicrographs, n=5-7 in each group). *P<0.05, ** P< 0.01, 
*** P< 0.001. 
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Effect of cAMP signaling on CPT-1a expression in primary hepatocytes 
To further examine if cAMP dependent signaling in hepatocytes influences 
CPT1A expression, we performed in vitro experiments using primary rat 
hepatocytes. Specifically, cells were treated with the cAMP specific protein 
kinase A (PKA) inhibitor, H89 (to decrease cAMP signaling), or the non-
degradable cAMP analog, dbcAMP (to increase cAMP signaling).  Western blot 
analysis of pCREB levels confirmed that PKA inhibition by H89 significantly 
decreased CREB phosphorylation (Figure 9A).  H89 treatment also lowered 
CPT1A mRNA levels (Figure 9B), whereas dbcAMP increased CPT1A 
expression (Figure 9B). Moreover, co-treatment of hepatocytes with H89 and 
dbcAMP mitigated the dbcAMP effect on CPT1A mRNA, demonstrating that the 
dbcAMP effect is significantly mediated by PKA (Figure 9B). These findings are 
in agreement with previous work demonstrating that cAMP signaling via CREB 
plays a critical role in the transcriptional regulation of CPT1A in hepatocytes [71]. 
Taken together, these results demonstrate that PDE4 mediated decrease in 
hepatic cAMP signaling contributes to alcohol induced reduction in hepatic 














Figure 9 A and B. Effect of cAMP signaling on hepatocyte Cpt1a mRNA 
expression. Rat primary hepatocytes were treated with PKA inhibitor, H89 (10 
µM) followed by dbcAMP (250 µM) for 24 hours. (A) pCREB levels in primary rat 
hepatocytes are decreased after H89 treatment. (B) Cpt1a mRNA expression in 
primary rat hepatocytes. Data are presented as mean ± S.D from 3 independent 













Effect of Pde4 inhibition on PPAR-α and PGC-1α 
Expression of the Cpt1a gene is critically regulated by the transcription 
factor PPAR-α and its coactivator, PGC-1α (PPAR gamma coactivator-1α) [70, 
76, 111]. Alcohol feeding has been shown to decrease hepatic PPAR-α levels 
[26]. Thus, we first examined whether PDE4 inhibition had any effect on PPAR-α. 
Western blot and real time PCR analysis of PPAR-α expression levels confirmed 
that alcohol lowered PPAR-α protein levels in WT-AF compared to WT-PF mice 
(Figure 10A, B). In contrast, PPAR-α levels were maintained in alcohol fed 
Pde4b-/- and Rolipram-treated mice (Figure 10A, B). Further, we examined 
whether PDE4 inhibition had any effect on PGC-1α levels. Alcohol feeding 
resulted in a modest but statistically non-significant decrease in hepatic PGC-1α 
mRNA levels (Figure 10C), as observed by other studies [74, 112]; however the 
levels were significantly higher in AF Pde4b-/- and Rolipram-treated AF mice 
compared to wild type AF mice (WT-AF) (Figure 10C). Western blot analysis of 
nuclear PGC-1α also confirmed the increase in PGC-1α levels in PDE4 inhibited 

















Figure 10A and B. PDE4 inhibition prevents alcohol-induced decrease of hepatic 
PPARα expression after 4 weeks of feeding. (A) Western blot analysis of nuclear 
PPARα protein levels. (Representative western blot n=5-7 in each group).  (B) 
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Figure 10C and D. PDE4 inhibition increases hepatic PGC-1α expression after 4 
weeks of feeding. (C) PGC-1α (Ppargc1a) mRNA levels were quantified by real 
time PCR. (n=5-7 in each group). (D) Western blot analysis of nuclear PGC-1α 
protein levels. Data are presented as mean ± S.D. (Representative western blot 
n=5-7 in each group). *P < 0.05, **P < 0.01. 


















Pde4 inhibition increases SIRT-1 expression 
 
SIRT1 deacetylase plays a critical role in the regulation of transcriptional 
activity of several transcription factors including PGC-1α [70, 112-115]. Increase 
in hepatic SIRT1 expression has been shown to attenuate alcoholic hepatic 
steatosis [92]. Importantly, previous studies have shown that agents which 
increase cAMP levels also increase SIRT1 expression and decrease hepatic 
steatosis [93, 116, 117]. Hence, we evaluated the effect of PDE4 inhibition on 
hepatic SIRT1 expression. Examination of hepatic SIRT1 mRNA levels showed 
that there was a modest increase in SIRT1 mRNA expression in WT-AF mice 
compared to WT-PF consistent with a previous report [118]; however, Pde4b-/- 
and Rolipram treated mice showed a significant increase in SIRT1 mRNA levels 
after alcohol feeding when compared to WT-AF mice (Figure 11A). 
Correspondent to mRNA levels, PDE4 inhibition also led to increased SIRT1 


















Figure11 A and B. PDE4 inhibition increases hepatic SIRT1 expression. (A) After 
4 weeks of feeding SIRT1 mRNA levels were quantified by real time PCR. (n=5-7 
in each group). (B) Western blot analysis of nuclear SIRT1 protein levels after 4 
weeks of feeding. Data are presented as mean ± S.D. (Representative western 
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Pde4 inhibition increases the expression of antioxidant enzymes  
Several studies have shown that alcohol decreases antioxidant enzymes 
contributing to increased oxidative stress, lipid peroxidation and steatosis. 
Previous studies also suggested that increased cAMP signaling mitigates 
oxidative stress in different animal models. Hence, we examined whether alcohol 
effect of antioxidant capacity of the liver could be prevented by PDE4 inhibition 
and prevention of decreased cAMP signaling. In agreement with the previous 
studies, we also observed decreased protein levels of SOD1 and Gpx2 in alcohol 
fed WT mice compared to PF-mice (Figure12A). Interestingly, alcohol feeding of 
Pde4b-/- mice not only did not decrease but increased protein levels of SOD1, 
SOD2, and GPx2 compared to WT mice (Figure 12A). Rolipram treatment also 
increased SOD1 and SOD2 protein levels but had no effect on GPx-2 (Figure 12 
A). Nrf2 is a transcription factor for different antioxidant enzymes, including 
SOD1/2 [119]. Hence, we next examined the effect of alcohol and PDE4 
inhibition on nuclear Nrf2 levels. Nuclear lysates were prepared from hepatic 
tissue and Western blot analyses performed to examine alcohol effect on Nrf2 
protein levels. Rolipram treated and PDE4B-/- PF mice had comparable levels of 
nuclear Nrf2 to WT-PF mice, however alcohol feeding resulted in lowering of Nrf2 
levels in WT mice compared to their PF counterparts (Figure 12B). 
Corresponding to increased SOD1/2 and GPx-2 levels in alcohol fed Rolipram-
treated and PDE4B-/- mice Nrf2 nuclear levels were maintained and were higher 







Figure 12 A and B. PDE4 inhibition leads to increased expression of Nrf2, 
CuZn/Mn superoxide dismutase (SOD,1/2) and glutathione peroxidase 2 (GPx-
2). Western blot analysis of hepatic tissue after 4 weeks of alcohol feeding. WT – 
wild type, PF –pair fed, AF –alcohol fed, ROL- Rolipram. (Representative 
western blot n=5-7 in each group). 
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cAMP analog (dbcAMP) increases NRF2 and SOD1/2 mRNA levels in 
primary hepatocytes 
Previous studies demonstrated that NRF2 expression and signaling is 
increased via cAMP/PKA/CREB pathway [120]. To further examine whether 
increased cAMP levels have an effect on NRF2 levels and NRF2 target genes, 
we treated primary rat hepatocytes with cAMP analog, dbcAMP (250 µM) and 
extracted total RNA after 24 hours of treatment. dbcAMP significantly increased 
NRF2, SOD1 and SOD2 mRNA levels compared to untreated hepatocytes 
(Figure 13). However, we did not observe any change in GPx mRNA levels at 




















Figure 13. dbcAMP treatment significantly increases Nrf2 and SOD1/2 mRNA 
levels in primary rat hepatocytes. Cells were treated with 250 µM dbcAMP for 24 
hours. NFR2, SOD1, SOD2 mRNA levels were quantified by real time PCR. Data 
are presented as the mean ± SD. n=3 *P < 0.05, **P<0.01, ***P<0.001 compared 





Pde4 inhibition decreases alcohol-induced kupffer cell activation and 
generation of 4-HNE and acrolein adducts 
Alcohol consumption is known to activate kupffer cells in the liver. Once 
activated they can increase radicals through NADH oxidase [38, 121-123] 
contributing to oxidative stress. Our previous work has shown that cAMP/PDE4 
pathway plays a critical role in Kupffer cell activation [7, 8]. Hence, we examined 
the effect of PDE4 inhibition in alcohol induced Kupffer cell activation by F4/80 
staining (Kupffer cell marker). As shown in (Figure 14A), WT-AF mice had 
significantly higher F4/80 staining compared to PF mice. However, alcohol fed 
mice treated with rolipram as well as Pde4b-/- mice showed decreased activation 
of kupffer cells (Figure 14A).  
We also examined the effect of PDE4 inhibition on alcohol induced lipid 
peroxidation by examining liver tissues for 4-HNE and acrolein adducts. As 
reported by others previously, alcohol feeding resulted in increased 4-HNE and 
acrolein staining in wild type mice (Fig.14B&C) indicating increased oxidative 
stress.  Notably, corresponding to increased SOD1 and GPx2 levels in alcohol 
fed PDE4B-/- and Rolipram treated WT mice, 4-HNE and acrolein staining was 
















Figure 14A and B.  PDE4 inhibition decreases alcohol-induced Kupffer cell 
activation (A), 4-HNE (B). After 4 weeks of alcohol feeding, livers were stained 
with F4/80 and 4-HNE antibodies. WT – wild type, PF –pair fed, AF –alcohol fed, 














Figure.14C. PDE4 inhibition decreases alcohol-induced acrolein formation. After 
4 weeks of alcohol feeding, livers were stained with Acrolein antibodies. WT – 
wild type, PF –pair fed, AF –alcohol fed, Rol- Rolipram. (Representative 





Pde4 inhibition restores AMPK-α activity and inactivates Acetyl-CoA- 
carboxylase 
AMPKα has been demonstrated to play a critical role in lipid metabolism, 
particularly in alcohol induced hepatic steatosis [62, 124]. AMPK mediated 
phosphorylation of inactivates Acetyl-CoA- carboxylase (ACC), a rate limiting 
enzyme in fatty acid synthesis, leads to inactivation of ACC and results in 
decreased lipid accumulation in the liver [62]. There are conflicting reports on 
alcohol effect on AMPK phosphorylation on Threonine 172 which activates 
AMPK kinase [62, 112, 124-128]. More recently, it has been shown that 
increased 4NHE levels lead to carbonylation of AMPK which inhibits its kinase 
activity [128].  Based on our observation that PDE4 inhibition attenuated 
oxidative stress and 4HNE adduct formation in alcohol fed mice, we examined 
whether PDE4 inhibition affected AMPK activity [59, 129]. Western blot analysis 
of phosphorylated AMPKα (Thr172) in liver lysates demonstrated that alcohol 
feeding led to a modest increase in pAMPKα levels (Figure 15A), however 
alcohol fed Pde4b-/- mice had higher pAMPK levels compared to wild type mice 
(Figure 15A). Additionally, examination of pACC levels by Western blot analysis 
showed that despite increased AMPK phosphorylation in alcohol fed WT mice, 
pACC levels were not increased (Figure 15B) indicating that AMPK kinase 
activity was affected by alcohol. However, alcohol fed Pde4b-/- mice had 
increased pACC levels suggesting that PDE4 inhibition resulted in restoring 














Figure 15A-B. PDE4 inhibition activates AMPKα and prevents alcohol-induced 
activation of Acetyl-CoA Carboxylase. A. Western blot analysis was performed 
for pAMPKα and AMPK protein levels in total liver lysates after 4 weeks of 
alcohol feeding. B. Western blot analysis of total liver lysates after 4 weeks of 
alcohol feeding showed that inactive state of ACC, as indicated by pACC (S79) 
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Alcoholic fatty liver is the first manifestation of alcoholic liver disease, and 
it develops in more than 90% of alcohol drinkers. Although steatosis is 
considered to be a benign condition, it has been demonstrated that the degree of 
steatosis positively correlates with the progression to more severe forms of ALD, 
such as alcoholic hepatitis and fibrosis [130-132]. The increase of lipogenesis 
and decrease of fatty acid β-oxidation contributes to the development of alcohol-
induced hepatic steatosis. Alcohol induced hepatic steatosis is mediated by 
dysregulated lipid metabolism largely involving impaired fatty acid β-oxidation 
[63].  
Although several studies have examined the impact of alcohol on β-
oxidation and the development of hepatic steatosis, the underlying mechanistic 
determinants are not completely elucidated. cAMP signaling has been shown to 
critically regulate lipid metabolism, including fatty acid β-oxidation [70, 71, 96, 
133]. Our earlier work demonstrated that chronic alcohol exposure can 
significantly induce PDE4 (B) expression and decrease cAMP levels in hepatic 
Kupffer cells and monocytes/macrophages, affecting LPS-inducible inflammatory 
gene expression [7, 8].  However, the effect of alcohol on hepatocyte PDE4 as a 
regulator of cAMP signaling in relation to lipid metabolism has never been 
investigated. Hence, in the present work, we examined the causal role of alcohol-
56 
 
induced hepatic PDE4 expression and compromised cAMP metabolism in the 
development of steatosis using pharmacological and genetic approaches. 
Our results show that alcohol significantly decreases hepatic cAMP levels 
early on in alcohol feeding following the upregulation of PDE4 expression. This 
decline in cAMP levels is accompanied by a correspondent decrease in pCREB 
levels and a reduction in CPT1A expression (a rate limiting enzyme in 
mitochondrial fatty acid β-oxidation). Importantly, alcohol effects on hepatic 
cAMP and CPT1A levels were abrogated by PDE4 inhibition via both 
pharmacological and genetic approaches. These findings suggested a pivotal 
role for PDE4 in decreasing hepatic cAMP levels in response to chronic alcohol 
feeding. Further, with regard to the involvement of a distinct PDE4 subfamily 
member, the data from Pde4b-/- animals strongly support the pathogenic 
involvement of PDE4B expression in the alcohol-induced decline in hepatic 
cAMP levels. Moreover, the key role of the gut-derived endotoxemia in ALD [134] 
also emphasizes the role of PDE4B, which is known to be endotoxin responsive 
[135-137].   
CPT1A expression is regulated by various transcription factors and co-
activators [70-72]. In experimental animal models of ALD, development of 
hepatic steatosis and reduction in CPT1A expression is attributed to a decreased 
expression and transcriptional activity of PPAR-α [26, 138] . Our results show 
that alcohol significantly decreased PPAR-α expression and this decline was 
associated with decreased hepatic cAMP levels. Importantly, the prevention of 
cAMP degradation by PDE4 inhibition prevented a decrease in PPAR-α. These 
57 
 
results could be explained by previous studies showing that cAMP promotes 
PPAR-α expression in hepatocytes [139]. It is well established that optimal 
transcriptional activity of PPAR-α requires a formation of a complex with its 
critical co-activator PGC-1α [70, 72]. PGC-1α  interacts and recruits proteins with 
histone acetylating activities which results in transcriptionally permissive 
promoter histone modification allowing increased transcription factor binding [88].  
PGC-1α in turn, has to be de-acetylated by SIRT1 to function as a co-activator 
[89, 90]. The roles of PGC-1α and SIRT1 in promoting PPAR-α mediated fatty 
acid β-oxidation have been extensively studied in alcohol induced hepatic 
steatosis [73-75, 91-93]. Our results show a marked increase in PGC-1α and 
SIRT1 expression in both Rolipram-treated and Pde4b-/- knockout alcohol fed 
mice when compared to wild type AF mice. These findings are in agreement with 
previous studies demonstrating that the proximal region of PGC-1α contains 
functional CREB binding sites which respond to increased cAMP levels by 
inducing PGC-1α mRNA [71, 89, 100, 139]. There are also several CREB binding 
sites in the SIRT1 promoter and CREB has been shown to increase SIRT1 
expression [117, 140]. With regard to SIRT1 expression in alcohol fed WT mice, 
decreased CREB levels did not seem to have a significant negative effect on 
SIRT1. This observation suggests that there are other mechanisms which play a 
role in SIRT1 transcriptional induction. Indeed, more recently, NFkB has been 
identified as a critical transcription factor for SIRT1 expression [141]. Hence, 
increased SIRT1 in AF WT mice could have been through NFkB which is known 
to be induced by alcohol feeding [142]. It is noteworthy that in addition to 
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transcriptional induction, SIRT1 activity could also be regulated by 
phosphorylation. In this regard, it has been shown that SIRT1 is activated by 
PKA-mediated phosphorylation [143]. Hence, it is possible that alcohol 
compromised cAMP/PKA signaling and reduced SIRT1 activity. Taken together, 
these results show that alcohol effect on hepatic PDE4 with a resultant decrease 
in cAMP/CREB levels contributes to decreased PPAR-α expression and 
transcriptional activity involving PGC-1α and SIRT1.  
In addition to impaired fatty acid β-oxidation, increased de novo 
lipogenesis contributes to alcohol induced hepatic steatosis [144]. Specifically, it 
has been shown that alcohol significantly attenuates AMPK activity which leads 
to increased activity of ACC, a rate limiting enzyme in fatty acid synthesis [62]. 
More recently, increased carbonylation of AMPK due to increased HNE 
production in alcohol fed mice has been shown to inhibit AMPK kinase function 
[128]. This loss of function led to decreased phosphorylation and activation of 
ACC [128]. Increased oxidative stress and reactive aldehydes is well 
documented with alcohol consumption [145-148]. Additionally, studies have 
shown the effect of alcohol on antioxidant enzymes including SODs, CAT and 
GPxs. As early as the late 80’s and mid 90’s it was observed that alcohol-treated 
rodents have decreased antioxidants activity compared to controls [149, 150]. 
And more recently it has been shown that alcohol can decrease the content GSH 
and expression of Nrf2 altogether with decreased activity of antioxidant enzymes 
[24-30]. In the present study we observed that alcohol can decrease SOD-1, Nrf2 
expression. Our results show that PDE4 inhibition and increased cAMP signaling 
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attenuated the formation of HNE and Acrolein adducts and Kupffer cell activation 
in alcohol fed mice. Importantly, there was a significant increase of SOD-2, GPx-
2 by PDE4 inhibition compared to WT-AF mice. These results are in agreement 
with other studies that cAMP signaling can mitigate oxidative stress is different 
animal models [151, 152]. Moreover, it has been shown that PGC-1α is required 
for the induction of ROS-detoxifying enzymes e.g. GPx1 and SOD-2 [153]. PGC-
1α stimulates NRF2 signaling and increased expression of mitochondrial 
detoxifying enzymes [153, 154]. Moreover, PGC-1α null mice have increased 
oxidative damage in neurons [153]. Therefore, our observations of increased 
NRF2 and antioxidant enzyme expression in PDE4B knockout mice could also 
be explained by increased PGC-1α expression. Taken together these results 
show that PDE4 inhibition prevents alcohol induced oxidative stress and 
formation of lipid peroxidation products. Decreased levels of reactive aldehyde 
adducts restores AMPK function and maintains ACC in inactive state which could 
lead to decreased lipid synthesis and hepatic steatosis in our model.  
In summary, we demonstrate for the first time that alcohol increases 
hepatic PDE4 expression leading to a decrease in cAMP levels and downstream 
cAMP/PKA/CREB signaling. Importantly, the data strongly support a predominant 
pathogenic role for PDE4B (among the PDE4 sub-family members) in the down-
regulation of CPT1A expression and consequent development of alcohol-induced 
hepatic steatosis. Additionally, PDE4 inhibition mitigates alcohol induced 
oxidative stress and attenuates fatty synthesis via AMPK/ACC pathway. It is 
noteworthy that the present work also identifies PDE4 as a potential therapeutic 
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target in the treatment of alcoholic fatty liver disease. Indeed, PDE4-specific 
inhibitors have been recently approved by the FDA for the treatment of certain 









SUMMARY AND CONCLUSIONS 
In conclusion, PDE4B plays an important pathogenic role in the development of 
hepatic steatosis and therefore PDE4B could serve as a therapeutic target for 












Figure 16. Summary and Conclusions. PDE4 inhibition enhanced AMPK activity 
and led to inactivation of ACC, a rate limiting enzyme in fatty acid synthesis. 
PDE4 inhibition also increased the expression of PGC-1α, SIRT-1, prevented 








Alcohol-induced diseases have been traditionally viewed as organ-specific 
processes, and interactions between different organ systems in the presence of 
alcohol are only beginning to be investigated. Hence, the major goal of the work 
pursued in this chapter was to examine the mechanisms involved in alcohol 
mediated brain inflammation in the context of gut-derived endotoxemia. Indeed, 
the brain is an important target for alcohol-induced damage, and recent work 
suggests that brain injury is often associated with gut-generated signals. 
 
I. Alcohol-induced neuro-inflammation: role of endotoxemia 
Chronic alcohol consumption could cause memory and cognitive deficits and 
neurodegeneration [159-163]. Moreover, several studies have shown that 
alcoholics had decreased white matter and neuronal loss [164-171]. Alcohol 
induced changes in the brain have been attributed to neuroinflammation. 
Specifically, alcohol has been shown to increase glial activation and pro-
inflammatory cytokines in the brain [172, 173].  
 Alcohol induced alterations in the gut microbiota (dysbiosis) can cause 
increased intestinal endotoxin production, as well as compromised gut barrier 
function, leading to increased intestinal permeability and translocation of bacteria 
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and bacterial products [174-179].  The frequency of systemic endotoxemia has 
been observed to be significantly greater in patients with alcoholic cirrhosis than 
in non-alcoholic cirrhotic subjects [180, 181].  Notably, plasma endotoxin levels 
are also significantly elevated in alcohol consuming subjects without evidence of 
liver disease [181] and non-alcoholic subjects experience transient endotoxemia 
following acute alcohol intake [180, 181].  These findings suggest a direct role for 
alcohol in inducing systemic endotoxemia.  
Recently, in a mouse model we have performed metagenomic analyses to 
examine the effects of chronic alcohol feeding on the gut bacterial microbiome by 
employing deep 16s rRNA gene sequencing using DNA isolated from fecal 
samples [179]. The findings from this study showed that alcohol feeding leads to 
significant shifts in the gut bacterial community with a marked increase in the 
phylum Proteobacteria which is comprised of gram negative bacteria that contain 
lipopolysaccharide (LPS/endotoxin) in their cell wall and are the principal source 
of intestinal endotoxin and systemic endotoxemia.   
 
II. Alcohol-induced neuro-inflammation: role of activated glial and production 
of inflammatory cytokines 
Glial cells (astrocytes and microglia) are resident macrophages in the brain 
representing the brain’s immune system. Glial cells respond to invading 
pathogens and cytokines by changing from a quiescent to an activated state 
releasing various toxic substances including cytokines and inflammatory 
mediators which contribute to neuronal damage. Activated microglial cells 
undergo morphological changes and have an increase expression of ionized 
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calcium binding adaptor molecule 1 (Iba-1), an adaptor molecule regulating 
calcium signals in the monocytic cells lines e.g. microglia [182, 183]. Glial 
fibrillary acidic protein (GFAP), is a bio-marker for astrocytic activation and its 
increase is known to be an indicator of reactive gliosis [184].  
Several studies have shown that ethanol increases astrocytic activation, 
indicated by glial fibrillary acidic protein GFAP and microglial activation indicated 
by Iba-1 in vivo and well as in vitro [185-187]. Importantly, alcohol induced 
oxidative stress in the brain leads to neuro-inflammation and neuronal damage. 
Crews et. al. showed that alcohol-fed mice had an increase of oxidative stress in 
the brain, indicated by elevated levels of the catalytic subunit of NAPDH oxidase 
gp91phox, ROS generation which can result in neuro-inflammation [188]. 
 
III. Toll like receptors (TLRs) and glial activation 
 TLRs are part of the pattern recognition family and are main regulators of 
inflammation. Upon binding of various ligands pathogen-associated molecular 
pattern molecules and D=damage-associated molecular pattern molecules 
(PAMPs and DAMPs), TLR4 downstream signaling gives rise to the production of 
inflammatory cytokines [189, 190]. Glial cells are able to detect invading 
pathogens through TLRs which leads to intracellular signaling and production of 
inflammatory cytokines and mediators such as TNFα, IL-6, IL-1β and nitric oxide 






Importantly, peripheral endotoxemia and resultant inflammation leads to 
increased levels of cerebral monocyte chemoattractant protein (MCP-1) which 
mediates immune cell infiltration into the brain [194]. Relevance of systemic 
endotoxemia, as a driver of brain inflammation, is significantly supported by the 
findings that a single administration of endotoxin significantly upregulates the 
expression of inflammatory mediators such as cyclooxygenase-2 (COX-2), IL-1β, 
TNF, and VCAM-1 in the brain [195]. 
Alcohol has been shown to activate TLR-4 signaling in glial cells through both 
MYD-dependent and independent way [189, 196, 197]. Several studies have 
shown that alcohol can also activate IL-1R transduction signaling. Particularly, 
alcohol has been shown to increase MyD88 expression and IRAK 
phosphorylation, which can trigger the activation of NF-kB/MAPK/JNK pathways. 
Further, alcohol has been shown to increase phosphorylation of ERK 1/2, p38, 
SAPK/JNK, and P38 MAPK followed by an increased activity of transcription 
factors AP-1 and NFkB/p65 [189, 196-198]. Alcohol mediated activation of 
MyD88 and downstream signaling leads to increased production of pro-
inflammatory cytokines IL-1β, TNF-α, IL-6 and COX-2. In comparison, it has 
been shown that alcohol also activates MyD88 independent pathway leading to 
the induction of phosphorylation of IRF-3, STAT-1 and IRF-1 expression and 
production of inflammatory mediators [196]. 
Besides PAMPs, recent studies have demonstrated that DAMPs also play 
important role in eliciting neuro- inflammation [190]. DAMPs are molecules that 
are released by injured or stressed cells  [190].  In the context of neurological 
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injury and inflammation, HMGB1 is a critical DAMP which signals through TLR-4, 
as well as other TLRs- TLR2 and TLR9 and RAGE  [190]. Importantly, alcohol 
has been shown to increase HMGB1 expression and signaling in the brain 
leading to inflammatory cytokine expression and inflammasome activation 
causing an increase in mature caspase-1 and IL-1β levels [199]. 
 
IV. Alcohol-induced neuro-inflammation: role of pde4 and cAMP and 
effect of pde4 inhibition 
Our earlier work has demonstrated that alcohol induced increase in PDE4 
expression and consequent decrease in intracellular cAMP plays a critical role in 
alcohol “priming” effect and exaggerated response of monocytes/macrophages to 
LPS; this phenotypic change is markedly modulated by cAMP analogues and 
cAMP-specific PDE4 inhibitors [7, 101, 200-202]. Further, studies using PDE4 
transgenic mice engineered by Conti and co-workers have demonstrated that 
PDE4 subfamily B (PDE4B) is involved in TLR4 signaling and is essential in LPS 
induced TNF-α production [135, 136]. With regard to endotoxin effect on the 
induction of PDE4 enzymes in the brain, it has been shown that LPS 
administration significantly upregulates PDE4B in astrocytes, microglia and 
endothelial cells along with mRNA levels of pro-inflammatory cytokines such as 
COX-2, IL-1β, TNF-α, and VCAM-1 in the brain [195, 203]. Detailed analysis of 
cell populations expressing PDE4B2 after endotoxin injection revealed that 
microglia, astrocytes and endothelial cells showed the highest expression of 
PDE4B2 [195]. Notably, PDE4 specific inhibitor Rolipram has been demonstrated 
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to significantly attenuate microglial activation in response to various stimuli, 
including endotoxin in several studies [191, 204-207]. These studies indicate a 
critical role of PDE4B in glial cell activation.  
In addition to LPS, inflammatory cytokines have a significant effect on cAMP 
levels via increased PDE4 enzyme expression in microglia cells. Specifically, 
extensive work by Pearse’s lab has shown that TNF and IL-1β rapidly deplete 
microglial cAMP levels by upregulating PDE4 enzyme expression/activity leading 
to COX-2 and iNOS production, similar to endotoxin [206, 208]. Significantly, 
both of these cytokines upregulate PDE4B2 expression in microglia [206]. 
Importantly, PDE4 inhibition prevents these effects of TNF and IL-1β in microglia 
[206, 208]. cAMP analogs have also been shown to protect microglial cells from 
ethanol-induced oxidative stress by decreasing ROS generation, and prevented 
decreased of antioxidant enzymes (GSH and catalase) [209].In addition, it has 
also been shown that cAMP analog could reverse alcohol effect on neuronal 
cAMP levels and mitochondrial respiration function by increasing PGC-1α levels 
[73, 210, 211]. 
Accordingly, to examine the mechanisms underlying alcohol induced brain 
inflammation, the studies pursued in this chapter examine the link between 
alcohol-induced systemic endotoxemia and brain- PDE4 expression and cAMP 







PDE4(B) plays  a critical pathogenic role in the development of alcohol-induced 
neuro-inflammation by regulating brain cAMP levels, glial activation and the 








Figure 17. PDE4 has a pathogenic role in alcohol-induced neuro-inflammation.  
Alcohol-induced gut-driven endotoxemia can lead to systemic inflammation, and 
translocation of pro-inflammatory cytokines into the blood brain barrier, leading to 











MATERIALS AND METHODS 
Animal Model: C57BL/6J and PDE4B knockout 3 months old male mice were 
pair-fed Lieber-DeCarli liquid diet (Lieber-DeCarli type, Bioserv, Frenchtown, NJ) 
containing either alcohol (AF) or isocaloric maltose dextrin (PF) for 4 weeks. 
Additional groups of AF and PF animals were treated with rolipram at 5 mg/kg, 3 
times a week. Mice were sacrificed at 1, 2 and 4 weeks after starting alcohol. 
LPS treatment: C57BL/6J and PDE4B knockout 3 months old male mice were 
intraperitoneally injected with a single dose of PBS or LPS (5 mg/kg) for 6 hours. 
LPS (Escherichia coli 0111:B4) was purchased from Difco (Detroit, 
MI). Before use, LPS was dissolved in sterile, pyrogen-free water, sonicated, and 
diluted with sterilized phosphate-buffered saline. 
Primary Microglial Isolation and Treatment:  Microglial cells were obtained 
from first postnatal day (P4) mice pups according to a slightly modified protocol 
[212, 213] which routinely yields about 0.5X105 cells/pup. Primary microglial cells 
were incubated in serum-free N-2 supplemented medium (recommended for 
growth of neuronal cells) and DMEM at a density of 0.3~0.5x106cells/ml and 
were exposed to ethanol (25-50mM) followed by stimulation with LPS (100 ng/ml).  
Western blot analysis: Brain tissue were lysed using RIPA buffer containing 
protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) and serine/threonine 
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phosphatase inhibitor sodium fluoride and phosphotyrosine phosphatase inhibitor 
sodium orthovanadate. Proteins (25 µg) were analyzed by SDS-polyacrylamide 
gel electrophoresis using a Bio-Rad (Hercules, CA) electrophoresis system. 
Immunoreactive bands were visualized using the enhanced chemiluminescence 
light detection reagents (Amersham, Arlington Heights, IL). Detection of GAPDH 
served as a loading control. Quantification was performed with Image 
LabTMSoftware (BioRad, Life Science Research, Hercules, CA). GFAP, GAPDH 
antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX), 
and PDE4B2 was a gift from Conti’s laboratory. 
RNA isolation and real-time PCR analysis: Total RNA was isolated from brain 
tissue using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). For RT-qPCR, the 
first-strand cDNA was synthesized using qScript cDNA SuperMix (Quanta 
Biosciences, Inc., Gaithersburg, MD). qRT-PCR was performed in triplicate with 
an ABI Prism 7500 sequence detection system and PerfeCTa SYBR Green 
FastMix, Low ROX reagents (Quanta Biosciences). The specific primers were 
purchased from integrated DNA technologies (IDT) (Coralville, Iowa). The 
parameter Ct (threshold cycle) was defined as the fraction cycle number at which 
the fluorescence passed the threshold. The relative gene expression was 























Table 2. Primers for quantitative reverse transcriptase-PCR  
Mouse Pde4a   
Pde4a_F  5'-CACAGCCTCTGTGGAGAAGTC-3' 
Pde4a_R  5'-GTGATACCAATCCCGGTTGTC-3' 
Mouse Pde4b   
Pde4b_F  5'-GACCGGATACAGGTTCTTCG-3' 
Pde4b_R  5'-CAGTGGATGGACAATGTAGTCA-3' 
Mouse Pde4d   
Pde4d_F  5'-TGTCCACAGTCAACGCCGGGAG-3' 




Immunohistochemistry: Brains were harvested from mice transcardially 
perfused with 20 ml PBS alone, followed by 15 ml of 4% paraformaldehyde 
(PFA) in PBS, pH 7.4. Brains were dissected and additionally fixed overnight at 
4ºC in 4% paraformaldehyde. Following fixation, brains were transferred to 30% 
sucrose solution and stored for 3 days at 4ºC. The tissue was then embedded in 
freezing media (Triangle biomedical sciences, Durham, NC), sectioned coronally 
at 30 µm on a cryostat, then mounted on microscope slides (Fisher Scientific, 
Pittsburgh, PA) and stored at -80ºC. Slides were warmed at 37°C for 20 minutes, 
and the tissue was blocked in TBS + 0.1% Triton X-100, 0.5% BSA, and 10% 
normal donkey serum for 1 hour at room temperature and then incubated 
overnight at 4°C with primary antibodies in blocking buffer, followed by incubation 
in secondary antibodies at room temperature for 1 hour. TRITC (1:200)-, FITC 
(1:200)-, CY5 (1:200)-, or AMCA (1:100)-conjugated secondary antibody F(ab’) 
fragments (all from donkey) and normal donkey serum (017-000-121) were 
purchased from Jackson Immunoresearch (West Grove, PA). Negative controls 
included appropriate species-specific non-immune IgGs instead of primary 
antibodies. All images were captured with a Nikon TE 300 inverted microscope 
equipped with a Spot CCD camera using identical exposure settings. Elements 
software (Nikon) was used to threshold baseline brightness and contrast 
identically for each image. Immunostaining was carried out for detecting the 
presence of activated astrocytes (GFAP; ab4674; Abcam; Cambridge, MA), 
microglia (Iba-1; 019,19741; Wako; Richmond, VA),  neurons (NeuN; ABN90P; 
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Millipore; Temecula, CA) and the pro-inflammatory cytokine cyclooxygenase-2 
(COX-2; 160126; Cayman Chemical; Ann Arbor, MI).  
Measurements of brain cAMP levels: Brain tissues were homogenized in 0.1N 
HCl and assayed according to the manufacturer instruction. cAMP ELISA kit was 
purchased  from Enzo Life Sciences (Farmingdale, NY).  
Cytokines Determination: Brain homogenates were homogenized in a buffer 
containing 20 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 1 mmol/L, PMSF, 
0.05% Tween-20, and a cocktail of protease inhibitors (Sigma) [214]. 
Concentrations of IL-1B, MCP-1, IL-17, and TNF-α in the brain were measured 
using Luminex100 reader (Luminex Corp., Austin, TX 78727, USA 
Endotoxin Assay: Serum endotoxin levels were measured using limulus 
amoebocyte lysate (LAL) gel-clot assay (Lonza®). The assay was performed 
according to the manufacturer’s instructions. 
Soluble CD14 ELISA: Serum samples were collected after centrifugation, and 
quantified using sCD14 ELISA (R&D systems) kit in accordance with the 
manufacturer’s instructions. 
Statistical Analysis: Statistical analysis was performed using GraphPad Prism 
Software. Data are presented as the mean ± standard deviation (SD). Statistical 
significance was calculated using one-way ANOVA followed by Bonferroni’s Test 








Chronic alcohol consumption induces systemic endotoxemia and brain 
inflammation 
To assess the effects of alcohol on the development of brain inflammation, 
we employed a well-established mouse model of alcohol feeding. This model 
shows intestinal barrier dysfunction, systemic endotoxemia and innate immune 
activation [199]. We first examined serum endotoxin levels for assessment of gut 
barrier function and soluble CD14 levels for gut microbial translocation and 
systemic monocyte/macrophage activation [215]. Indeed, chronic alcohol feeding 
for 2 weeks led to a significant increase in serum endotoxin and sCD14 levels 
(Figure 18) demonstrating that in our animal model alcohol feeding caused gut 
barrier dysfunction and systemic immune activation.  
Since systemic endotoxemia was evident in our animal model, we then 
examined the effect of chronic alcohol feeding on the development of brain 
inflammation. Brain inflammation was assessed by examining the glial activation 
utilizing immunohistochemical analysis. In animals chronically fed alcohol for two 
weeks, a robust activation of astrocytes was observed in the hippocampus-
dentate gyrus indicated by GFAP expression (Figure 19B), along with an 
activation of microglia in the cerebral cortex, indicated by Iba-1 expression (Fig. 
19B) as seen in other studies [185-187]. Finally, we evaluated the effect of 
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alcohol on COX-2 expression, a generalized marker for brain inflammation [216, 
217]. Correspondent to glial activation there was a significant upregulation of 
COX-2 expression in the hippocampus-CA3 region in the AF-mice compared to 
PF mice (Fig. 19B). These data suggest that chronic alcohol consumption 









Figure 18. Alcohol increases systemic endotoxemia and sCD14 levels in mice. 
Serum from pair-fed and alcohol-fed mice measured using LAL assay. Data are 











Figure 19A. Schematic of brain regions. Red squares denote brain regions 
imaged. CA3 region (A-B), and dentate gyrus (C-D) of the hippocampus, and 











































Figure 19B. Alcohol induced glial activation and neuro-inflammation.  Expression 
of COX2 (purple, A-B; hippocampus-CA3 region), astrocytic activation marker 
GFAP (red, C-D; hippocampus-dentate gyrus), and microglial marker Iba-1 
(green, E-F; cerebral cortex) are up-regulated within the brains of mice exposed 
to alcohol for two weeks relative to pair-fed animals. Hoescht (blue) and NeuN 
(purple) staining are used as nuclear and neuronal markers, respectively.  
Images are representative of the inflammatory state of the whole brains of their 





Chronic alcohol consumption increases pde4b expression and decreases 
camp levels in the brain 
Our earlier work has demonstrated that alcohol and LPS-inducible 
inflammatory cytokine production in peripheral monocyte/macrophages is 
critically regulated by increased PDE4 expression and a consequent decrease in 
cellular cAMP [7, 8].  
Since microglia are the important brain resident macrophages, we initially 
examined the effect of alcohol and LPS on PDE4 expression. Microglial cells 
obtained from first postnatal day (P1) mice pups were treated with ethanol (25 
mM; 48 h) followed by LPS (100 ng/ml; 4 h). Ethanol by itself induced significant 
increase in TLR4 and PDE4B expression with no effect on PDE4A and D 
expression (Figure 20A and B). As expected, LPS treatment alone led to a robust 
increase only in PDE4B expression. Importantly, in relevance to alcohol 
responsive brain inflammatory effects, ethanol treated microglia showed a 
significant enhancement in LPS-inducible PDE4B expression (Figure 20B). 
Further, induction of PDE4B protein expression and activation of microglial cells 
was also confirmed by immunohistochemical analyses. LPS-inducible PDE4B 
expression strongly correlated with the increase in Iba-1 expression, a marker of 
microglial activation (Figure 20C). Additionally, we examined the effect of high 
mobility group box 1(HMGB1) on microglial PDE4 expression. Similar to LPS, 
treatment of microglial cells with recombinant HMGB1 (5µg/ml) upregulated 
PDE4B and TNF mRNA levels without a significant effect on PDE4A and D. 
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 Subsequently we examined the effect of chronic alcohol consumption on 
brain PDE4B expression in AF mice that experience an increase in systemic 
endotoxin levels and brain inflammation indicated by COX-2 expression. Brain 
homogenates obtained after 2 weeks of alcohol feeding were assessed by 
western blot analysis. In comparison to PF mice, a significant induction of PDE4B 
expression was observed in the brain homogenates of AF mice (Figure 21A); 
however, there was no change in PDE4 A and D expression (data not shown). 
Importantly, commensurate with the observed increase in PDE4B protein 
expression we observed a significant decline in cAMP levels in the brain 
homogenates of AF mice (Figure 21B). Taken together, these data suggest that 
alcohol and endotoxin (LPS) play a contributory role in the pathogenic increase in 





















Figure 20. A) Alcohol significantly increases TLR-4 mRNA levels in primary 
microglial cells. B) Alcohol and LPS selectively induce PDE4B expression in 
mouse primary microglial cells with no effect on PDE4A and D. UT-untreated, 
EtOH-ethanol, 25mM for 48h, LPS, 100ng/ml for 4h. mRNA levels were analyzed 















Figure 20 C and D. The effect of LPS and HMGB1 on primary microglial cells. C. 
PDE4B and IBA-1 expression is induced by LPS in primary mouse microglial 
cells.  Immunostaining of purified mouse microglial cells stimulated with 100ng/ml 
LPS for 6hrs, and double-stained for IBA-1 and PDE4B. D. rHMGB-1 induces 
only PDE4B and TNF expression in primary microglial cells. mRNA levels of 
PDE4A,B,D and TNF were quantified using real time PCR in primary microglial 
cells treated with rHMGB-1 (5µg/ml) for 3h. n=3. *p<0.05, **<0.01 
 



















Figure 21. Alcohol increased PDE4B protein expression and decreases cAMP 
levels in the brain. Immunoblot analysis of brain homogenates from wild type 
(WT) mice that were PF and AF for 2 weeks. (Representative western blot n=5-7 
in each group). A) Brains from pair-fed and alcohol-fed mice were lysed, and 
cellular cAMP levels were measured. B) Obtained cAMP values were normalized 
by protein content. Data are presented as means and SD. (n=5-7 in each group). 
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The effect of pde4 inhibition on glial activation and inflammation 
 Previous studies have shown that endotoxin mediated increase in PDE4B 
expression in the brain leads to an increase in glial activation and inflammatory 
markers [195]. Accordingly, the causal role of alcohol-induced brain PDE4B 
expression in glial activation was examined by employing both pharmacological 
and genetic approaches that inhibit PDE4B. Along with chronic alcohol feeding, 
rolipram, a well-established PDE4-specific inhibitor that can cross the blood brain 
barrier (BBB) was administered i.p (5 mg/kg; 3 times/week). Moreover, relevance 
of PDE4B inhibition was also examined in PDE4B knockout (PDE4B KO) animals.  
Initially, the efficacy of PDE4 inhibition by both approaches was assessed by 
evaluating their effect on the brain cAMP levels. Alcohol induced decrease in 
brain cAMP levels was prevented in PDE4B KO as well as WT animals treated 
with Rolipram (Figure 22A). Taken together, these data strongly support the 
notion that alcohol-induced PDE4B expression plays a contributory role in the 
decrease of brain cAMP levels.  
 Further, in the context of the regulatory role of PDE4 expression in glial 
activation, immunohistochemical analysis was performed on the brain tissue 
obtained from 2 week alcohol-fed animals with and without rolipram treatment. 
Significantly, there was a marked attenuation of alcohol-induced GFAP and 
COX-2 expression by rolipram (Figure 22B). Additionally, examination by 
immunoblotting analysis of brain homogenates from WT and PDE4B KO animals 
showed a complete inhibition of alcohol-induced GFAP expression that was seen 
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in WT animals (Figure 22C). Overall, these data strongly support the causal role 
of PDE4B expression in glial activation induced by chronic alcohol consumption. 






Figure 22A. PDE4 inhibition prevents alcohol-mediated decrease in brain cAMP 
levels. Brains from pair-fed and alcohol-fed mice were lysed, and cellular cAMP 
levels were measured. Obtained cAMP values were normalized by protein 











Figure 22B. Up-regulation of COX2 and astrocytic activation marker (GFAP) 
following chronic alcohol exposure is significantly diminished by rolipram. Images 
are representative of the inflammatory state of the whole brain of their respective 







Figure 22C. Alcohol-induced increase in expression of brain astrocytic GFAP is 
prevented in PDE4B KO mice. Immunoblot analysis of WT and PDE4B KO mice 
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Pde4b knockout mice do not exhibit glial activation in response to 
systemic endotoxin administration 
Since previous studies demonstrated that endotoxin administration leads 
to a concomitant increase in brain PDE4B and glial activation, we examined 
whether LPS-inducible PDE4B induction in the brain plays a causal role or 
mediates this inflammatory response. Wild type and PDE4B knockout mice were 
injected with 5 mg/kg LPS for 6 hours and brain tissues were examined for glial 
activation markers. LPS administration resulted in Iba1 and CD11b expression in 
wild type mice demonstrating microglial activation (Figure 23A). Further, LPS 
administration increased astrocyte marker expression indicated by GFAP 
staining (Figure 23B). Importantly, all glial activation markers were significantly 
lower in the brain tissues of PDE4B knockout mice after LPS administration 
















Figure 23A and B.  PDE4B knockout mice are protected from endotoxin-induced 
glial activation. Expression of CD11b/c, GFAP, and Iba-1  are up-regulated within 
the brains of mice after 6 hours of LPS exposure. Images are representative of 





The effect of pde4 inhibition on alcohol induced proinflammatory cytokine 
production and neuro-inflammation 
To further assess the effect of PDE4B inhibition on alcohol-induced 
inflammatory response, brain homogenates were analyzed for cytokines by 
Milliplex cytokine kit. Commensurate with the increased activation of glial 
markers, we observed a significant increase in inflammatory cytokines TNF, IL-
1β, IL-17 and inflammatory chemokine MCP-1 in wild type alcohol fed mice 
(Figure 24). In comparison, PDE4B knockout and Rolipram treated mice had 
significantly lower levels of these cytokines after alcohol feeding demonstrating a 
















Figure 24. PDE4 inhibition prevents alcohol-induced neuro-inflammatory 
cytokines/chemokines. Brains from pair-fed and alcohol-fed mice were lysed, and 
neuro-inflammatory cytokines/chemokines were measured. Obtained values 
were normalized by protein content. Data are presented as mean ± S.D (n=5-7 in 






Significant scientific advances have been made to understand deleterious 
effects of alcohol consumption on individual systems such as brain, liver, immune, 
cardiovascular, and endocrine systems. However, pathogenic interactions 
between different organ systems in the presence of alcohol are only beginning to 
be investigated. There are emerging data suggesting that these interactions 
could provide important insights into the mechanisms by which alcohol-induced 
pathology in one organ influences the functioning of other organs. Hence this 
study examined the role of gut associated events occurring in response to 
chronic alcohol consumption and development of brain inflammation.  
Alcohol induced neuro-inflammation has been demonstrated in different 
mouse models ranging from 10 day alcohol gavage followed by endotoxin 
administration to chronic Leiber de Carli alcohol feeding model [199, 218]. The 
Lieber De Carli diet has been extensively used for studying the pathogenesis of 
alcoholic liver disease and has also recently been used to examine alcohol-
induced neuro-inflammation [199, 219]. Significantly, there are pathogenic 
changes in the gut barrier function leading to increased intestinal permeability 
and systemic endotoxemia and inflammation in the Lieber De Carli alcohol 
feeding model [179]. Hence, this model of chronic alcohol feeding was utilized in 
the present study to examine the link between alcohol-induced systemic 
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endotoxemia and development of brain inflammation [219, 220]. Indeed, results 
of our study showed that alcohol feeding significantly increased endotoxin levels. 
More importantly, this rise in endotoxin levels was also accompanied by 
increased sCD14 (Figure 18). These results indicate that alcohol feeding led to 
gut dysfunction and translocation of microbial products resulting in the activation 
of systemic innate response. Correspondent to increased endotoxemia and 
activation of innate response, alcohol was observed to induce brain inflammatory 
changes as demonstrated by glial cell activation (Figure 19B). Having 
established a model of chronic alcohol induced brain inflammation, the 
underlying pathogenic mechanisms were investigated.  
With regards to the systemic inflammatory changes induced by alcohol our 
earlier data showed that alcohol induces PDE4 expression in circulating as well 
as hepatic monocytes/macrophages [7]. Moreover, increased PDE4 expression 
plays a critical role in the priming effects of alcohol leading to induction and 
exacerbation of LPS-inducible inflammatory cytokine expression. Interestingly, 
analogous to the peripheral inflammatory responses and cytokine production, 
alcohol was also observed to induce PDE4B expression in the brain microglial 
cells as well as total brain homogenates (Figure 20A and Figure 21A). Also, 
similar to peripheral monocytes/macrophages, alcohol exposure exacerbated 
LPS-inducible PDE4B expression in microglial cells (Figure 20A). Interestingly, 
alcohol treatment only affected expression of PDE4B, with minimal to no effect 
on PDE4A and D sub-family members. These data strongly support the notion 
that alcohol predominantly affects PDE4B expression that affects brain cAMP 
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metabolism. Although, LPS through TLR activation is a strong driver of PDE4B 
expression in peripheral monocytes/macrophages, it is well-documented that 
very little peripheral LPS gains access to the brain due to the poor passage 
through the blood brain barrier [135-137, 221]. Hence, the alcohol-induced 
systemic endotoxemia likely plays an indirect role in inducing brain PDE4B 
expression and inflammation via the triggering of systemic cytokines such as 
TNF. Indeed, TNF and other cytokines have been shown to induce PDE4B 
expression and inflammatory changes in glial cells [206]. Since the brain glial 
cells that are initially activated by systemic cytokines also produce more 
inflammatory cytokines they can further induce and sustain PDE4B expression in 
an autocrine loop in the brain. Besides cytokines, PDE4B expression could also 
be induced via activation of TLRs, particularly TLR4 in glial cells. In this regard, 
our results show that alcohol increases TLR4 expression in microglial cells and 
this increase in TLR4 is accompanied by an increase in PDE4B expression 
(Figure 20A and B). Activation of TLR4 on glial cells and induction of PDE4B 
expression could also be driven by localized DAMPs such as HMGB1 which are 
produced during alcohol-induced neuro-inflammation and injury and can act as 
ligands and activate TLR signaling [199, 222, 223]. Importantly, our results show 
that HMGB1 significantly upregulates PDE4B expression in microglial cells. 
Taken together, in the context of brain inflammatory changes obtained data 
suggest that gut derived endotoxemia and systemic inflammation likely initiate 
the induction of PDE4B expression in the brain tissue in the alcohol-fed animals.   
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 The functional consequence of alcohol induced brain PDE4B expression 
is demonstrated by a substantial decline in cAMP levels (Figure 21B). cAMP 
helps to maintain immune homeostasis by suppressing the release of 
proinflammatory mediators (e.g., TNF-α, IL-17, and IFN-γ) and promoting the 
release of anti-inflammatory mediators (e.g., IL-10) by immune cells. Hence, 
similar to our observations related to systemic/hepatic inflammatory responses, 
the induction of PDE4 expression and decrease in cAMP levels possibly plays a 
key regulatory role in alcohol-induced glial cell activation and inflammatory 
cytokine expression in the brain. Notably, the causal role of PDE4B 
expression/activity in alcohol-induced glial cell activation and brain inflammation 
was strongly supported by using a pharmacologic inhibitor, as well as PDE4B 
knockout mice. Specifically, lack of PDE4B expression in PDE4B knockout mice 
as well as inhibition of its activity by Rolipram prevented alcohol-induced 
decrease in brain cAMP levels. These data strongly suggest that alcohol induced 
alterations and brain cAMP homeostasis are predominantly regulated by PDE4B 
expression. Significantly, inhibition of PDE4 expression/activity and prevention of 
decline in cAMP levels markedly attenuated glial cell activation and brain 
inflammatory cytokine production. The attenuating effect of PDE4 inhibition on 
alcohol-induced brain inflammation could be occurring (i) indirectly, via 
suppression of systemic/hepatic inflammation as well as (ii) directly, via 
suppression of inflammatory cytokine expression by activated glial cells. 
Moreover, since inflammatory cytokines can further activate and sustain PDE4 
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expression in glial cells, PDE4 inhibition could also impact the autocrine loop of 
PDE4B activation, inflammatory signaling and cytokine production.  
 In summary, the data obtained identifies and establishes that alcohol 
mediated increase in PDE4B expression plays a critical pathogenic role in 
alcohol-induced neuro-inflammation. In relevance to clinical applications, the 
studies not only elucidate the mechanistic role of PDE4B, but also demonstrate 
that it is a significant therapeutic target for alcohol-induced neuro-inflammation 







SUMMARY AND GENERAL DISCUSSION 
 
 
Major findings:  
 
Alcohol exposure leads to early increase of PDE4 expression resulting in a 
sustained downregulation of hepatic cAMP signaling 
 cAMP signaling has been shown to critically regulate lipid metabolism in 
different cell types including hepatocytes. Our previous studies have shown that 
alcohol significantly decreases cellular cAMP levels via upregulation of PDE4 
expression and activity in macrophages including Kupffer cells [7, 8]. Accordingly, 
studies in this dissertation were designed to examine whether alcohol affects 
hepatic cAMP/PDE4 homeostasis and its relevance to dysregulated lipid 
metabolism and development of hepatic steatosis. Our results show that alcohol 
indeed significantly upregulated hepatocyte PDE4 expression as early as in 1 
week after alcohol feeding. As a functional consequence of PDE4 expression, 
there was a significant decrease in hepatic cAMP levels in a sustained manner. 
This was followed by significant downregulation of hepatic cAMP signaling as 
indicated by decreased pCREB levels. Importantly, these changes occurred in 





PDE4 plays a causal role in the development of alcohol-induced hepatic 
steatosis 
Alcohol mediated increase in gut permeability and systemic endotoxemia 
along with increased hepatic inflammatory cytokines and oxidative alcohol 
metabolism contribute to the development of hepatic steatosis [134, 179]. cAMP 
elevating agents, including PDE4 inhibitors, have been shown to have anti-
inflammatory and anti-oxidant effect in several cell types. Our previous work has 
shown that endotoxin significantly upregulates PDE4B expression in Kupffer cells 
without any effect on other PDE4s [7]. Moreover, PDE4 inhibitor, Rolipram 
significantly attenuates LPS-inducible TNF production by Kupffer cells. Based on 
these observations and obtained data that alcohol increases PDE4 enzyme 
expression in hepatic tissue, we examined whether PDE4 upregulation played a 
causal role in the development of alcohol induced hepatic steatosis. To test this 
hypothesis we used two approaches to inhibit PDE4 activity, pharmacological 
and genetic. PDE4 sub-family consists of 4 different genes (PDE4A through D). 
Pde4a, Pde4b and Pde4d knockout mice have been generated and used by 
several investigators to study the role of these PDE4 enzymes in different studies. 
Since endotoxemia plays a critical role in the development of ALD, we chose to 
use Pde4b knockout mice in this study. Our results showed that alcohol induced 
increase in hepatic fatty acid accumulation were significantly attenuated by PDE4 
inhibition suggesting a causal role of PDE4 enzymes in this process. These 
results also indicate that inhibition of PDE4B is sufficient to prevent alcohol 
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induced hepatic steatosis. What role do other PDE4s plays in ALD needs to be 
investigated in future studies.  
 
PDE4 inhibition prevents alcohol mediated decrease in cAMP 
signaling and CPT1A expression 
cAMP signaling has been shown to modulate expression of several genes 
involved in lipid metabolism [96, 97, 224-226]. Our results show that alcohol 
feeding decreased expression of CPT1A (a rate limiting enzyme in fatty acid b-
oxidation) along with cAMP/pCREB levels. pCREB is a critical transcription factor 
for CPT1A [71]. cAMP elevating agents have been shown to induce CPT1A 
transcription via increased pCREB and HNF4α binding to cAMP response unit 
(CRU) in CPT1A gene promoter (Figure 25,[71]). Moreover, cAMP-mediated 
increase in PGC1α further promotes CPT1A transcription [121]. Importantly, 
PGC1α activity is modulated by SIRT-1-dependent deacetylation. Our results 
show that PDE4 inhibition prevented alcohol induced decrease in pCREB levels 
and increased PGC1α and SIRT-1 expression in alcohol fed mice. Further, 
alcohol mediated decrease in PPARα expression was also prevented by PDE4 
inhibition. Taken together, we demonstrate that PDE4 inhibition prevents alcohol 
induced decrease in CPT1A expression via PPARα/PGC1α/SIRT1 pathway. 
These findings also suggest that alcohol- induced increase in hepatic PDE4, 
specifically PDE4B expression, and compromised cAMP signaling predisposes 









Figure 25: Transcriptional regulation of CPT1A gene by different transcription 
factors and co-activators. This scheme illustrates transcription factor binding sites 





PDE4 inhibition increases the expression of antioxidant enzymes and 
restores AMPK-α activity 
Oxidative stress and lipid peroxidation play a crucial role in the 
development of alcohol-induced hepatic steatosis and progression of ALD [227, 
228]. Several studies have shown that cAMP pathway modulates the expression 
of antioxidants and antioxidant enzymes [229-231]. Our results show that alcohol 
induces oxidative stress and lipid peroxidation was markedly attenuated by PDE4 
inhibition. This rescue could be attributed to increased NRF2 signaling and 
expression of antioxidant enzymes [39, 40]. Consequently, decrease in 4HNE-
adduct formation could have contributed to increased activity of AMPKα and a 
resultant inactivation of ACC. These results are in agreement with the studies 
demonstrating that 4HNE-mediated carbonylation of AMPKα impairs its kinase 
function [128]. Taken together, these findings indicate that PDE4 inhibition 
mediated increase of antioxidant enzymes, AMPKα function and decreased 
activity of ACC also contributed to decreased lipid accumulation in alcohol fed 
mice.  
 
Chronic alcohol consumption induces systemic endotoxemia and brain 
inflammation 
 Alcohol-induced neuro-inflammation has been associated with gut-induced 
systemic inflammation. It is well-established that alcohol induces increase in gut 
permeability and dysbiosis leading to increased endotoxemia. Systemic 
endotoxemia promotes activation of immune cells and production of pro-
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inflammatory cytokines in many organs including the liver. Endotoxin also 
triggers the activation of endothelial cells in BBB through TLR2 and TLR4 
receptors which lead to production of cytokines by endothelial cells. Cytokines 
generated by these endothelial cells and Kupffer cells in the liver can cross BBB 
and induce activation of glial cells. Relevant to our studies, it has been shown 
that cytokine-induced activation of glial cells is critically mediated by PDE4B 
[206]. Moreover, systemic LPS administration significantly increases PDE4B 
expression in endothelial and glial cells in the brain [195]. Our results show that 
alcohol feeding increased serum endotoxin levels which was accompanied by 
increased immune cell activation indicated by sCD14. Correspondent to these 
changes, we observed increased glial activation and inflammation in the brain. 
Importantly, alcohol increased PDE4B expression in both microglia (in vitro) and 
in the brain leading to significant decrease in cAMP levels. PDE4 inhibition 
prevented glial activation and inflammation suggesting that PDE4, specifically 
PDE4B plays a causal role in alcohol induced neuro-inflammation. Another 
important finding of this study was the effect of recombinant HMGB1 on PDE4B 
expression in microglial cells. Increased HMGB1 levels are reported with alcohol 
consumption and shown to induce neuro-inflammation through activating 
inflammasome pathway and IL-1β production [199]. Taken together, these results 
suggest that PDE4B induction by alcohol feeding not only plays a causal role in 




 Significance and Clinical Relevance 
In the United States, there is about 80,000 deaths each year due 
excessive alcohol consumption [3], and about 2.5 million deaths each year world-
wide [4]. Chronic alcohol consumption can affect many organs including the liver 
and brain.  Currently there are no FDA approved therapies available for the 
treatment of ALD and alcohol-induced neuro-inflammation. The most widely-used 
(off-label) drug therapies for ALD are glucocorticoids and pentoxifylline (PTX). 
Unfortunately, an important subset of AH patients treated with glucocorticoids 
have “steroid resistance”, and some patients have contraindications to steroid 
therapy [232]. Pentoxifylline, a broad spectrum PDE inhibitor with only a weak 
PDE4 inhibitor activity, has been clinically used to treat alcoholic hepatitis and 
the data available from the limited studies indicate a possible positive 
intervention effect on all-cause mortality and mortality due to the hepatorenal 
syndrome  [233]. Treatment of alcohol-induced pathological changes that act as 
precursors to the development of advanced liver pathologies is highly desirable.  
With regard to alcohol-induced neuro-inflammation, there are potential 
therapeutic targets including TNF-α, however, when treating ALD patients with 
anti-TNF-α antibodies, the benefits were not as expected [190]. Anakinra, a 
recombinant IL-1 receptor antagonist, showed beneficial effects in alcohol-fed 
mice by preventing activation of the inflammasome complex, and increase of pro-
inflammatory cytokines [199].   
Our study shows for the first time, that PDE4B could be a therapeutic 




There are several strengths to this dissertation. First strength is that it 
identifies the causal role of PDE4B in the development of alcohol induced hepatic 
steatosis as well as neuro-inflammation. Secondly, this study uses PDE4B 
knockout mice to investigate the role of PDE4B in alcohol induced pathologies in 
the liver and brain. These studies also pinpoint to compromised cAMP signaling 
as a major predisposing factor to impaired fatty acid oxidation and development 
of neuro-inflammation.  
Additionally, this dissertation emphasizes in the importance of the gut-
liver-brain axis, how different organs interact with each other in the presence of 
alcohol. The brain is an important target for alcohol-induced damage, and recent 
work suggests that brain injury is often associated with gut-generated signals. 
Strength of this dissertation is that a change in cAMP/PDE4B homeostasis has 
been identified as a common pathway disturbed with alcohol in the liver and brain. 
Importantly, a specific PDE4B inhibitor could offer therapeutic benefits to patients 
with ALD, or other alcohol-induced pathologies including neuro-inflammation. 
The Lieber De Carli diet that we used was a very useful tool to simulate 
the American diet and human chronic alcohol drinking [220, 234]. Rodents are 
given 5% of ethanol in the liquid diet, which is similar to a strong beer. In 
comparison to a human (70kg), it is approximately to 700g per day or six bottles 
of wine [235], however, mice and rats metabolize alcohol 3-5 times faster rate 
than humans [235, 236], resulting in approximately similar blood alcohol levels of 
a regular drinker (100-150 mg/dl) [235]. Mice from our study had comparable 
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blood alcohol levels between 100 to 150 mg/dl (Figure 6C). Additionally, the 
Lieber De Carli diet prevented the natural aversion rodents have to alcohol, and 
prevented differences between the calories consumed within the groups [220, 
234]. Importantly, the Lieber De Carli diet is the best model to mimic the initial 
stage of ALD (e.g. steatosis) [220]. 
 Moreover, we used primary hepatocytes and microglia in some of our 
experiments, instead of immortalized cultured cells. Primary cells are not as 
prone to have phenotypic changes as immortalized cells. Immortalized cells are 
mostly derived from tumors and can exhibit significant differences with regards to 
signal transduction pathways and gene expression patterns leading to 
phenotypic and morphological differences [237]. In this regard, critical information 
on the effect of alcohol and pathogenic expression of PDE4 was obtained from 
primary hepatocytes and microglia. Importantly, the data obtained from primary 
cells on alcohol-mediated changes in PDE4 expression correlated with the in vivo 
observations in the liver and brain tissue samples (Figure 5 & 20).  
 
Weakness 
There are several weaknesses in this study. One major weakness is that 
the animal model used in this study does not fully recapitulate human ALD. 
Additionally, there are several mechanisms involved in the development of 
alcohol-induced hepatic steatosis. cAMP pathway has been shown to affect the 
expression of lipogenic genes, which are elevated with alcohol consumption. We 
did not examine what is the effect of increased PDE4 expression on this pathway. 
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Additionally, we observed increase in all PDE4 expression (PDE4A-PDE4D), but 
we do not know what impact other PDE4s have on alcohol induced dysregulation 
of lipid metabolism. It is also possible that PDE4s have the role in alcohol-
induced hepatic injury. We did observe that Rolipram decreased ALT levels in 
alcohol fed mice, but we did not investigate the mechanisms of this protection.  
Shearn et al. have shown that 4-HNE can induce AMPK carbonylation 
therefore inhibiting its function to phosphorylate downstream targets such as 
ACC  [128]. We suggested that AMPK function could be impaired by 
carbonylation, but we failed to show AMPK carbonylation. Additionally, we 
observed decreased of HNE-adduct formation in alcohol fed Rolipram and 
knockout group, and this could be due to decreased lipid content.  
Another limitation is that animal models are not always translational. To 
date, there are no mouse models that develop all stages of ALD, and there is still 
not much research done on the interaction between organs in the presence of 
alcohol. In our studies we used PDE4 inhibitor which can cross BBB. This 
approach cannot be used in humans, since this class of inhibitors has side 
effects like nausea and emesis. Our PDE4B knockout mice also are whole body 
knockouts. So it is difficult to say where we intervened in terms of gut-liver-brain 
interactions. Did we affect the liver and attenuated inflammatory cytokine release 
in the systemic circulation? Is it why we see less inflammation in the brain? Or 
we affected both organs simultaneously? These are the limitations of our 
approach in this dissertation.  
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FDA approved PDE4 inhibitors (Roflumilast and Apremilast) are designed 
to not cross BBB to avoid side effects like nausea and emesis. Use of these 
inhibitors and liver specific PDE4B knockouts in our studies could have answered 
the question whether we affected liver-brain axis. 
 
Future Directions 
Do alcohol-mediated temporal changes in gut bacterial composition correlate 
with the alcohol-induced liver/brain pathologies? 
Our group has recently characterized the changes in intestinal bacterial 
communities after 8 weeks of chronic alcohol feeding in mice by deep 16S rRNA 
gene sequencing and showed significant shifts in the intestinal microbiome [179]. 
This study showed that there was a marked increase in the Proteobacteria 
phylum which is comprised of Gram negative bacteria containing 
lipopolysaccharide (LPS; endotoxin) in their cell walls [179]. In future, it will be 
important to investigate the temporal changes in the gut microbiome and the 
intestinal permeability and correlate these changes with the development of liver 








How does alcohol upregulate PDE4 in the liver and brain? What are the 
underlying epigenetic mechanisms of this upregulation? 
There are not many studies describing how PDE4 enzymes are regulated 
transcriptionally. Work done by our group demonstrated that histone lysine 9 
trimethylation (H3K9me3) in the Pde4b2 intronic promoter region plays a major 
role in regulating endotoxin responsive PDE4B2 mRNA expression in 
macrophages [137]. Specifically, a rapid and significant decline in the PDE4B2 
promoter-H3K9 trimethylation occurs in response to endotoxin leading to 
PDE4B2 transcriptional activation and mRNA expression [137]. We have not 
investigated the promoter-associated epigenetic modifications contributing to the 
induction of PDE4s in the liver and brain in the presence of alcohol. In this regard, 
alcohol can lead to epigenetic modifications of promoter histones resulting in 
increased transcription factor binding.  
 
Will probiotics prevent alcohol mediated liver and brain inflammation and injury? 
Modulation of the intestinal microbiota is an emerging strategy to reduce 
bacterial translocation and circulating endotoxin levels. When ingested, probiotic 
bacteria can colonize the gut, thereby changing the gut microflora and gut lumen 
leading to improved gut barrier integrity. Alcoholics have altered bowel flora 
compared to healthy controls and short-term oral supplementation with probiotics 
has been shown to restore the bowel flora and ameliorate liver injury compared 
to standard therapy [238]. Lactobacillus rhamnosus Gorbach-Goldin (LGG) unlike 
other Lactobacilli consistently colonizes the intestine. LGG has been widely 
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studied in the treatment of intestinal disorders and has been observed to 
maintain and improve intestinal barrier function and ameliorate oxidative stress 
and liver injury in a rat model of alcoholic steatohepatitis (ASH) [178].  Our group 
also showed the efficacy of LGG supplementation in preventing alcohol-induced 
pathogenic alterations in the intestinal microbiome and liver injury in the mouse 
model of ALD [179]. Hence, it will be important to evaluate the therapeutic 
efficacy of probiotics in attenuating alcohol mediated liver and brain inflammation 

































Summary and Conclusions: 
 This dissertation was built upon the hypothesis that alcohol-induced PDE4 
expression and decreased cellular cAMP levels play critical pathogenic role in 
alcohol-induced hepatic steatosis and neuro-inflammation. Using both in vitro 
and in vivo approaches our studies showed that that alcohol induced increase in 
hepatic and brain PDE4, specifically PDE4B expression. This increase was 
accompanied by significant decrease in cAMP levels and downstream signaling. 
PDE4-mediated compromised cAMP signaling predisposed the liver to impaired 
b-oxidation and oxidative stress. Increase in PDE4 in the brain resulted in glial 
cell activation and neuro-inflammation. Importantly, PDE4 inhibition reversed the 
changes induced by alcohol in both organs. Specifically, PDE4 inhibition in the 
liver increased PGC1α and SIRT1 levels and prevented the decrease in CPT1A 
expression. Additionally, there was an increase in anti-oxidant enzyme 
expression and decreased oxidative stress upon PDE4 inhibition in alcohol fed 
mice. In the brain, PDE4 inhibition could prevent the activation of glial cells and 
the development of inflammation. Overall, the studies in this dissertation identify 
PDE4B as a potential therapeutic target for the treatment of alcoholic fatty liver 


















Figure 26. PDE4 inhibition could serve as a therapeutic target for alcohol-induced 
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